190 results on '"Parissiadis A"'
Search Results
2. Anti-Donor HLA Antibody Response After Pancreatic Islet Grafting: Characteristics, Risk Factors, and Impact on Graft Function
- Author
-
Pouliquen, E., Baltzinger, P., Lemle, A., Chen, C.-C., Parissiadis, A., Borot, S., Frimat, L., Girerd, S., Berney, T., Lablanche, S., Benhamou, P.Y., Morelon, E., Badet, L., Dubois, V., Kessler, L., and Thaunat, O. more...
- Published
- 2017
- Full Text
- View/download PDF
Catalog
3. Does a Useful Test Exist to Properly Evaluate the Pathogenicity of Donor-specific Antibodies? Lessons From a Comprehensive Analysis in a Well-studied Single-center Kidney Transplant Cohort
- Author
-
Gautier Vargas, Gabriela, Olagne, Jérome, Parissiadis, Anne, Joly, Mélanie, Cognard, Noelle, Perrin, Peggy, Froelich, Nadine, Guntz, Philippe, Gachet, Christian, Moulin, Bruno, and Caillard, Sophie
- Published
- 2020
- Full Text
- View/download PDF
4. Matching for the nonconventional MHC-I MICA gene significantly reduces the incidence of acute and chronic GVHD
- Author
-
Carapito, Raphael, Jung, Nicolas, Kwemou, Marius, Untrau, Meiggie, Michel, Sandra, Pichot, Angélique, Giacometti, Gaëlle, Macquin, Cécile, Ilias, Wassila, Morlon, Aurore, Kotova, Irina, Apostolova, Petya, Schmitt-Graeff, Annette, Cesbron, Anne, Gagne, Katia, Oudshoorn, Machteld, van der Holt, Bronno, Labalette, Myriam, Spierings, Eric, Picard, Christophe, Loiseau, Pascale, Tamouza, Ryad, Toubert, Antoine, Parissiadis, Anne, Dubois, Valérie, Lafarge, Xavier, Maumy-Bertrand, Myriam, Bertrand, Frédéric, Vago, Luca, Ciceri, Fabio, Paillard, Catherine, Querol, Sergi, Sierra, Jorge, Fleischhauer, Katharina, Nagler, Arnon, Labopin, Myriam, Inoko, Hidetoshi, von dem Borne, Peter A., Kuball, Jürgen, Ota, Masao, Katsuyama, Yoshihiko, Michallet, Mauricette, Lioure, Bruno, Peffault de Latour, Régis, Blaise, Didier, Cornelissen, Jan J., Yakoub-Agha, Ibrahim, Claas, Frans, Moreau, Philippe, Milpied, Noël, Charron, Dominique, Mohty, Mohamad, Zeiser, Robert, Socié, Gérard, and Bahram, Seiamak more...
- Published
- 2016
- Full Text
- View/download PDF
5. Evolution of humoral lesions on follow-up biopsy stratifies the risk for renal graft loss after antibody-mediated rejection treatment
- Author
-
Antonin Bouchet, Brieuc Muller, Jerome Olagne, Thomas Barba, Mélanie Joly, Augustin Obrecht, Maud Rabeyrin, Frédérique Dijoud, Cécile Picard, Sarah Mezaache, Antoine Sicard, Alice Koenig, Anne Parissiadis, Valérie Dubois, Emmanuel Morelon, Sophie Caillard, and Olivier Thaunat more...
- Subjects
Graft Rejection ,Transplantation ,Isoantibodies ,Nephrology ,Biopsy ,Graft Survival ,Humans ,Kidney Transplantation ,Antibodies ,Retrospective Studies ,Follow-Up Studies - Abstract
Background The standard-of-care protocol, based on plasma exchanges, high-dose intravenous immunoglobulin and optimization of maintenance immunosuppression, can slow down the evolution of antibody-mediated rejection (AMR), but with high interindividual variability. Identification of a reliable predictive tool of the response to AMR treatment is a mandatory step for personalization of the follow-up strategy and to guide second-line therapies. Methods Interrogation of the electronic databases of 2 French university hospitals (Lyon and Strasbourg) retrospectively identified 81 renal transplant recipients diagnosed with AMR without chronic lesions (cg score ≤1) at diagnosis and for whom a follow-up biopsy had been performed 3–6 months after initiation of therapy. Results The evolution of humoral lesions on follow-up biopsy (disappearance versus persistence versus progression) correlated with the risk for allograft loss (logrank test, P = .001). Patients with disappearance of humoral lesions had ∼80% graft survival at 10 years. The hazard ratio for graft loss in multivariate analysis was 3.91 (P = .04) and 5.15 (P = .02) for patients with persistence and progression of lesions, respectively. The non-invasive parameters classically used to follow the intensity of humoral alloimmune response (evolution of immunodominant DSA mean fluorescence intensity) and the decline of renal graft function (estimated glomerular filtration rate decrease and persistent proteinuria) showed little clinical value to predict the histological response to AMR therapy. Conclusion We conclude that invasive monitoring of the evolution of humoral lesions by the mean of follow-up biopsy performed 3–6 months after the initiation of therapy is an interesting tool to predict long-term outcome after AMR treatment. more...
- Published
- 2022
- Full Text
- View/download PDF
6. Impact of KIR/HLA genetic combinations on double umbilical cord blood transplantation outcomes. Results of a French multicentric retrospective study on behalf of the Société Francophone de Greffe de Moelle et de Thérapie Cellulaire (SFGM-TC) and the Société Francophone d’Histocompatibilité et d’Immunogénétique (SFHI)
- Author
-
Rettman, P, Malard, F, Legrand, N, Avinens, O, Eliaou, J-F, Picard, C, Dormoy, A, Lafarge, X, de Matteis, M, Kennel, A, Loiseau, P, Devys, A, Boudifa, A, Absi, L, Fort, M, Masson, D, Quainon, F, Theodorou, I, Batho, A, Parissiadis, A, Delbos, F, Drouet, M, Senitzer, D, Marry, E, Raus, N, Yakoub-Agha, I, Cesbron, A, Retière, C, and Gagne, K more...
- Published
- 2016
- Full Text
- View/download PDF
7. Pre‐existing donor‐specific antibodies are detrimental to kidney allograft only when persistent after transplantation
- Author
-
Caillard, Sophie, Becmeur, Camille, GautierVargas, Gabriela, Olagne, Jerome, Muller, Clotilde, Cognard, Noelle, Perrin, Peggy, Braun, Laura, Heibel, Francoise, Lefebre, Francois, Renner, Veronique, Gachet, Christian, Moulin, Bruno, and Parissiadis, Anne more...
- Published
- 2017
- Full Text
- View/download PDF
8. Evolution of humoral lesions on follow-up biopsy stratifies the risk for renal graft loss after antibody-mediated rejection treatment
- Author
-
Bouchet, Antonin, primary, Muller, Brieuc, additional, Olagne, Jerome, additional, Barba, Thomas, additional, Joly, Mélanie, additional, Obrecht, Augustin, additional, Rabeyrin, Maud, additional, Dijoud, Frédérique, additional, Picard, Cécile, additional, Mezaache, Sarah, additional, Sicard, Antoine, additional, Koenig, Alice, additional, Parissiadis, Anne, additional, Dubois, Valérie, additional, Morelon, Emmanuel, additional, Caillard, Sophie, additional, and Thaunat, Olivier, additional more...
- Published
- 2022
- Full Text
- View/download PDF
9. Survenue d’une thrombopénie sévère et durable, au décours d’une greffe de moelle allogénique, imputable à l’existence chez l’hôte d’une allo-immunisation anti-HPA-1
- Author
-
Parissiadis, A., Bilger, K., Laplace, A., Berceanu, A., Schwebel, M., Froelich, N., Cazenave, J.-P., Hanau, D., Tourne, S., and Lioure, B.
- Published
- 2010
- Full Text
- View/download PDF
10. EVOLUTION OF THE DSA ABILITY TO FIX C1Q IN A COHORT OF 118 SENSITIZED KIDNEY TRANSPLANT RECIPIENTS: 79
- Author
-
Gautier-Vargas, G., Caillard, S., Parissiadis, A., Olagne, J., Muller, C., Perrin, P., Braun, L., Heibel, F., Froelich, N., Gachet, C., and Moulin, B.
- Published
- 2015
11. A NEW DIAGNOSTIC TOOL FOR ANTIBODY MEDIATED REJECTION IN HEART AND LUNG TRANSPLANTATION: INTRAGRAFT DONOR SPECIFIC ANTI-HLA ANTIBODIES DETECTION: 8
- Author
-
Olagne, J., Parissiadis, A., Froelich, N., Caillard, S., Marcellin, L., Epailly, E., Kremer, H., Hirschi, S., Kessler, R., and Moulin, B.
- Published
- 2015
12. A NEW DIAGNOSTIC AND PRONOSTIC TOOL FOR ANTIBODY MEDIATED REJECTION IN KIDNEY TRANSPLANTATION: INTRAGRAFT DONOR SPECIFIC ANTI-HLA ANTIBODIES DETECTION: 3
- Author
-
Olagne, J., Parissiadis, A., Caillard, S., Froelich, N., Marcellin, L., Braun-Parvez, L., Gautier-Vargas, G., Heibel, F., Muller, C., Perrin, P., Gachet, C., and Moulin, B.
- Published
- 2015
13. Prospective Measures of Adherence by Questionnaire, Low Immunosuppression and Graft Outcome in Kidney Transplantation
- Author
-
Olivier Thaunat, Françoise Hau, Mathilde Prezelin-Reydit, Isabelle Etienne, Laetitia Albano, Virginie Renac, Valérie Dubois, Cécile Vigneau, Monique Pourtein, Sophie Caillard, A. Parissiadis, Jonathan Visentin, Jean-Luc Taupin, Gwendaline Guidicelli, Lionel Couzi, Christophe Mariat, Benoit Barrou, Lena Absi, Pierre Merville, CHU Bordeaux [Bordeaux], AURAD Aquitaine, Bordeaux population health (BPH), Université de Bordeaux (UB)-Institut de Santé Publique, d'Épidémiologie et de Développement (ISPED)-Institut National de la Santé et de la Recherche Médicale (INSERM), EFS, Cellules B normales et pathogéniques - Normal and pathogenic B cell responses (NOPAB), Centre International de Recherche en Infectiologie (CIRI), École normale supérieure de Lyon (ENS de Lyon)-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Université Jean Monnet - Saint-Étienne (UJM)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-École normale supérieure de Lyon (ENS de Lyon)-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Université Jean Monnet - Saint-Étienne (UJM)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), CHU Strasbourg, Immuno-Rhumatologie Moléculaire, Université de Strasbourg (UNISTRA)-Institut National de la Santé et de la Recherche Médicale (INSERM), Biologie et pharmacologie des plaquettes sanguines: hémostase, thrombose, transfusion, Université de Strasbourg (UNISTRA)-EFS-Institut National de la Santé et de la Recherche Médicale (INSERM), CHU Rouen, Normandie Université (NU), Hôpital Pasteur [Nice] (CHU), Ischémie Reperfusion en Transplantation d’Organes Mécanismes et Innovations Thérapeutiques ( IRTOMIT), Université de Poitiers-Institut National de la Santé et de la Recherche Médicale (INSERM), CHU Charles Foix [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Immunologie humaine, physiopathologie & immunothérapie (HIPI (UMR_S_976 / U976)), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris Cité (UPCité), Centre Hospitalier Universitaire de Saint-Etienne [CHU Saint-Etienne] (CHU ST-E), Etablissement français du sang, Auvergne-Loire [Saint-Etienne] (EFS), Etablissement Français du Sang, École des Hautes Études en Santé Publique [EHESP] (EHESP), Institut de recherche en santé, environnement et travail (Irset), Université d'Angers (UA)-Université de Rennes (UR)-École des Hautes Études en Santé Publique [EHESP] (EHESP)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Structure Fédérative de Recherche en Biologie et Santé de Rennes ( Biosit : Biologie - Santé - Innovation Technologique ), Etablissement français du sang [Rennes] (EFS Bretagne), Composantes innées de la réponse immunitaire et différenciation (CIRID), Université Bordeaux Segalen - Bordeaux 2-Centre National de la Recherche Scientifique (CNRS), Université de Bordeaux (UB), Hôpital Edouard Herriot [CHU - HCL], Hospices Civils de Lyon (HCL), Université Claude Bernard Lyon 1 (UCBL), Université de Lyon, France REIN AQUITAINE, Centre International de Recherche en Infectiologie - UMR (CIRI), Institut National de la Santé et de la Recherche Médicale (INSERM)-École normale supérieure - Lyon (ENS Lyon)-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Centre National de la Recherche Scientifique (CNRS)-Institut National de la Santé et de la Recherche Médicale (INSERM)-École normale supérieure - Lyon (ENS Lyon)-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Centre National de la Recherche Scientifique (CNRS), EFS-Université de Strasbourg (UNISTRA)-Institut National de la Santé et de la Recherche Médicale (INSERM), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Paris (UP), Centre Hospitalier Universitaire de Saint-Etienne (CHU de Saint-Etienne), Structure Fédérative de Recherche en Biologie et Santé de Rennes ( Biosit : Biologie - Santé - Innovation Technologique )-Institut National de la Santé et de la Recherche Médicale (INSERM)-École des Hautes Études en Santé Publique [EHESP] (EHESP)-Université de Rennes 1 (UR1), Université de Rennes (UNIV-RENNES)-Université de Rennes (UNIV-RENNES)-Université d'Angers (UA), Chard-Hutchinson, Xavier, École normale supérieure - Lyon (ENS Lyon)-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-École normale supérieure - Lyon (ENS Lyon)-Université Claude Bernard Lyon 1 (UCBL), and Université de Lyon-Université de Lyon-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS) more...
- Subjects
medicine.medical_specialty ,medicine.medical_treatment ,[SDV]Life Sciences [q-bio] ,030232 urology & nephrology ,graft survival ,kidney transplantation ,030230 surgery ,Logistic regression ,HLA Sensitization ,Article ,03 medical and health sciences ,0302 clinical medicine ,Morisky scale ,Internal medicine ,medicine ,adherence ,Kidney transplantation ,immunosuppression ,business.industry ,Immunosuppression ,General Medicine ,medicine.disease ,Predictive value ,3. Good health ,[SDV] Life Sciences [q-bio] ,body regions ,Calcineurin ,Medicine ,Trough level ,business ,dnDSA - Abstract
Background: Non-adherence with immunosuppressant medication (MNA) fosters development of de novo donor-specific antibodies (dnDSA), rejection, and graft failure (GF) in kidney transplant recipients (KTRs). However, there is no simple tool to assess MNA, prospectively. The goal was to monitor MNA and analyze its predictive value for dnDSA generation, acute rejection and GF. Methods: We enrolled 301 KTRs in a multicentric French study. MNA was assessed prospectively at 3, 6, 12, and 24 months (M) post-KT, using the Morisky scale. We investigated the association between MNA and occurrence of dnDSA at year 2 post transplantation, using logistic regression models and the association between MNA and rejection or graft failure, using Cox multivariable models. Results: The initial percentage of MNA patients was 17.7%, increasing to 34.6% at 24 months. Nineteen patients (8.4%) developed dnDSA 2 to 3 years after KT. After adjustment for recipient age, HLA sensitization, HLA mismatches, and maintenance treatment, MNA was associated neither with dnDSA occurrence, nor acute rejection. Only cyclosporine use and calcineurin inhibitor (CNI) withdrawal were strongly associated with dnDSA and rejection. With a median follow-up of 8.9 years, GF occurred in 87 patients (29.0%). After adjustment for recipient and donor age, CNI trough level, dnDSA, and rejection, MNA was not associated with GF. The only parameters associated with GF were dnDSA occurrence, and acute rejection. Conclusions: Prospective serial monitoring of MNA using the Morisky scale does not predict dnDSA occurrence, rejection or GF in KTRs. In contrast, cyclosporine and CNI withdrawal induce dnDSA and rejection, which lead to GF. more...
- Published
- 2021
- Full Text
- View/download PDF
14. Evolution and Impact of Pre-Existing Donor Specific Antibodies in a Monocentric Cohort of Adult Kidney Transplant Recipients.: Abstract# A148
- Author
-
Caillard, S., Flick, C., Parissiadis, A., Vargas, Gautier G., Olagne, J., Perrin, P., Muller, C., Braun, L., Heibel, F., Gachet, C., and Moulin, B.
- Published
- 2014
15. Identification and Long-Term Consequences of Antibodies Which Bound C1q in 118 Kidney Transplant Recipients With Donor Specific Antibodies.: Abstract# A129
- Author
-
Vargas, Gautier G., Caillard, S., Parissiadis, A., Olagne, J., Froelich, C., Perrin, P., Braun, L., Heibel, F., Gachet, C., and Moulin, B.
- Published
- 2014
16. Prospective Measures of Adherence by Questionnaire, Low Immunosuppression and Graft Outcome in Kidney Transplantation
- Author
-
Prezelin-Reydit, Mathilde, primary, Dubois, Valérie, additional, Caillard, Sophie, additional, Parissiadis, Anne, additional, Etienne, Isabelle, additional, Hau, Françoise, additional, Albano, Laetitia, additional, Pourtein, Monique, additional, Barrou, Benoît, additional, Taupin, Jean-Luc, additional, Mariat, Christophe, additional, Absi, Léna, additional, Vigneau, Cécile, additional, Renac, Virginie, additional, Guidicelli, Gwendaline, additional, Visentin, Jonathan, additional, Merville, Pierre, additional, Thaunat, Olivier, additional, and Couzi, Lionel, additional more...
- Published
- 2021
- Full Text
- View/download PDF
17. Does a Useful Test Exist to Properly Evaluate the Pathogenicity of Donor-specific Antibodies? Lessons From a Comprehensive Analysis in a Well-studied Single-center Kidney Transplant Cohort
- Author
-
Mélanie Joly, Nadine Froelich, Peggy Perrin, Philippe Guntz, Jérôme Olagne, Gabriela Gautier Vargas, Christian Gachet, Noëlle Cognard, Bruno Moulin, Sophie Caillard, and A. Parissiadis
- Subjects
Graft Rejection ,Male ,Time Factors ,Biopsy ,030230 surgery ,Single Center ,Gastroenterology ,0302 clinical medicine ,HLA Antigens ,Isoantibodies ,Child ,Kidney ,medicine.diagnostic_test ,biology ,Complement Fixation Tests ,Graft Survival ,Middle Aged ,medicine.anatomical_structure ,Treatment Outcome ,Complement C3d ,Child, Preschool ,Cohort ,030211 gastroenterology & hepatology ,Female ,Antibody ,Adult ,medicine.medical_specialty ,Adolescent ,Renal function ,03 medical and health sciences ,Young Adult ,Monitoring, Immunologic ,Predictive Value of Tests ,Internal medicine ,medicine ,Humans ,Clinical significance ,Aged ,Retrospective Studies ,Transplantation ,business.industry ,Donor specific antibodies ,Complement C1q ,Reproducibility of Results ,Kidney Transplantation ,body regions ,biology.protein ,business ,Biomarkers - Abstract
Background Donor-specific antibodies (DSA) play a major role in antibody-mediated rejection (AMR) and graft dysfunction. However, the clinical relevance of complement-binding anti-HLA antibodies remains unclear. Methods Here, we analyzed DSA detected in the serum (sDSA) using single antigen bead, C1q, and C3d assays combined with the study of intragraft DSA (gDSA) in 86 patients who had DSA and underwent a kidney biopsy for cause (n = 58) or without evidence of kidney dysfunction (n = 28). DSA characteristics were collected and related to the presence of AMR, graft histological features, and allograft survival. Results Forty-five patients (52%) had C1q DSA, and 42 (51%) had C3d DSA. Allograft biopsies revealed AMR in 63 cases (73%), regardless of kidney function. gDSA were identified in 74% of biopsies. We observed a strong correlation among single antigen bead mean fluorescence intensity and complement assays positivity, presence of gDSA, and AMR occurrence. Conclusions Complement-binding DSA per se were not significantly associated with allograft survival in the entire study sample. Finally, gDSA predicted subsequent graft loss in patients who showed a stable renal function at the day of biopsy. Our data suggest that DSA mean fluorescence intensity and presence of gDSA might provide prognostic information during posttransplant monitoring. more...
- Published
- 2020
18. Compatibility at amino acid position 98 of MICB reduces the incidence of graft-versus host disease in conjunction with the CMV status
- Author
-
Philippe Moreau, Machteld Oudshoorn, Catherine Paillard, Valérie Dubois, Raphael Carapito, Irina Kotova, Antoine Toubert, Ismail Aouadi, Perrine Spinnhirny, Eric Spierings, A. Parissiadis, Ibrahim Yakoub-Agha, Mauricette Michallet, Myriam Labalette, Seiamak Bahram, Régis Peffault de Latour, Jürgen Kuball, Mohamad Mohty, Christophe Picard, Bronno van der Holt, Didier Blaise, Ryad Tamouza, Myriam Maumy-Bertrand, Frédéric Bertrand, Pascale Loiseau, Véronique Rolli, Jan J. Cornelissen, Aurore Morlon, Anne Cesbron, Gérard Socié, Yasuo Morishima, Peter A. von dem Borne, Frans H.J. Claas, Cécile Macquin, Angélique Pichot, Bruno Lioure, Dominique Charron, Katia Gagne, Equipe Plate-forme GENOMAX (Inserm U1109), Fédération Hospitalo-Universitaire OMICARE-Fédération de Médecine Translationnelle de Strasbourg (FMTS), Université de Strasbourg (UNISTRA)-Université de Strasbourg (UNISTRA)-Immuno-Rhumatologie Moléculaire, Université de Strasbourg (UNISTRA)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Strasbourg (UNISTRA)-Institut National de la Santé et de la Recherche Médicale (INSERM), LabEx Transplantex [Strasbourg], Université de Strasbourg (UNISTRA), INSERM Franco-Japanese Nextgen HLA Laboratory [Strasbourg] (FJ-HLA), Laboratoire International Associé (LIA), INSERM Franco-Japanese Nextgen HLA Laboratory[Nagano], Pôle de Biologie - Laboratoire d’Immunologie [Nouvel Hôpital Civil, Strasbourg] (Plateau Technique de Biologie), Nouvel Hôpital Civil - NHC [Strasbourg], BIOMICA SA [Strasbourg], Etablissement Français du Sang [Nantes], Hôpital Edouard Herriot [CHU - HCL], Hospices Civils de Lyon (HCL), Immunobiology of Human αβ and γδ T Cells and Immunotherapeutic Applications (CRCINA-ÉQUIPE 1), Centre de Recherche en Cancérologie et Immunologie Nantes-Angers (CRCINA), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Nantes - UFR de Médecine et des Techniques Médicales (UFR MEDECINE), Université de Nantes (UN)-Université de Nantes (UN)-Centre hospitalier universitaire de Nantes (CHU Nantes)-Centre National de la Recherche Scientifique (CNRS)-Université d'Angers (UA)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Nantes - UFR de Médecine et des Techniques Médicales (UFR MEDECINE), Université de Nantes (UN)-Université de Nantes (UN)-Centre hospitalier universitaire de Nantes (CHU Nantes)-Centre National de la Recherche Scientifique (CNRS)-Université d'Angers (UA), Europdonor operated by Matchis Foundation [Leiden], Leiden University Medical Center (LUMC), Erasmus MC Cancer Institute, Rotterdam, Laboratoire d'Immunologie [Lille], Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille), Lille Inflammation Research International Center - U 995 (LIRIC), Institut Pasteur de Lille, Réseau International des Instituts Pasteur (RIIP)-Réseau International des Instituts Pasteur (RIIP)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Lille-Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille), University Medical Center [Utrecht], Anthropologie bio-culturelle, Droit, Ethique et Santé (ADES), Aix Marseille Université (AMU)-EFS ALPES MEDITERRANEE-Centre National de la Recherche Scientifique (CNRS), Ecotaxie, microenvironnement et développement lymphocytaire (EMily (UMR_S_1160 / U1160)), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Paris (UP), Etablissement Français du Sang - Grand Est (EFS - alsace strasbourg), Etablissement français du sang - Auvergne-Rhône-Alpes (EFS), Les Hôpitaux Universitaires de Strasbourg (HUS), Institut de Recherche Mathématique Avancée (IRMA), Université de Strasbourg (UNISTRA)-Centre National de la Recherche Scientifique (CNRS), Hopital Saint-Louis [AP-HP] (AP-HP), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Institut Paoli-Calmettes, Fédération nationale des Centres de lutte contre le Cancer (FNCLCC), Erasmus University Medical Center [Rotterdam] (Erasmus MC), Institute for Translational Research in Inflammation - U 1286 (INFINITE (Ex-Liric)), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Lille-Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille), Hôpital Hôtel-Dieu [Paris], CHU Saint-Antoine [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Université Pierre & marie Curie, Centre de Recherche Saint-Antoine (CR Saint-Antoine), Sorbonne Université (SU)-Institut National de la Santé et de la Recherche Médicale (INSERM)-CHU Saint-Antoine [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Aichi Cancer Center Research Institute, This work was supported by grants from the Agence Nationale de la Recherche (ANR) (ANR-11-LABX-0070_TRANSPLANTEX), and the INSERM (UMR_S 1109), the Institut Universitaire de France (IUF), all to SB, from the University of Strasbourg (IDEX UNISTRA) to CP and SB, from the European regional development fund (European Union) INTERREG V program (project n°3.2 TRIDIAG) to RC and SB, and from MSD-Avenir grant AUTOGEN to SB., We would like to thank Prof. Robert Zeiser (University of Freiburg/Germany) for critical reading of this manuscript. We thank Martin Verniquet for critical review of statistical analyses. We would also like to thank Nicole Raus (SFGM-TC, Lyon, France) for retrieving the clinical data from the ProMISe database., Immuno-Rhumatologie Moléculaire, Université de Strasbourg (UNISTRA)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Strasbourg (UNISTRA)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Fédération Hospitalo-Universitaire OMICARE-Fédération de Médecine Translationnelle de Strasbourg (FMTS), Université de Strasbourg (UNISTRA)-Université de Strasbourg (UNISTRA), Université d'Angers (UA)-Université de Nantes (UN)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Centre hospitalier universitaire de Nantes (CHU Nantes)-Université d'Angers (UA)-Université de Nantes (UN)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Centre hospitalier universitaire de Nantes (CHU Nantes), Universiteit Leiden, Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris Cité (UPCité), Université Pierre et Marie Curie - Paris 6 (UPMC), Centre de Recherche Saint-Antoine (CRSA), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Sorbonne Université (SU), Hematology, Erasmus MC other, and Bernardo, Elizabeth more...
- Subjects
medicine.medical_specialty ,Congenital cytomegalovirus infection ,Graft vs Host Disease ,[SDV.CAN]Life Sciences [q-bio]/Cancer ,Disease ,Gastroenterology ,03 medical and health sciences ,0302 clinical medicine ,Immune system ,[SDV.CAN] Life Sciences [q-bio]/Cancer ,Internal medicine ,medicine ,Humans ,Typing ,Amino Acids ,Retrospective Studies ,Transplantation ,business.industry ,Incidence (epidemiology) ,Incidence ,Hazard ratio ,Hematopoietic Stem Cell Transplantation ,Hematology ,medicine.disease ,3. Good health ,Graft-versus-host disease ,030220 oncology & carcinogenesis ,Cytomegalovirus Infections ,business ,030215 immunology - Abstract
International audience; Graft-versus-host disease (GVHD) and cytomegalovirus (CMV)-related complications are leading causes of mortality after unrelated-donor hematopoietic cell transplantation (UD-HCT). The non-conventional MHC class I gene MICB, alike MICA, encodes a stress-induced polymorphic NKG2D ligand. However, unlike MICA, MICB interacts with the CMV-encoded UL16, which sequestrates MICB intracellularly, leading to immune evasion. Here, we retrospectively analyzed the impact of mismatches in MICB amino acid position 98 (MICB98), a key polymorphic residue involved in UL16 binding, in 943 UD-HCT pairs who were allele-matched at HLA-A, -B, -C, -DRB1, -DQB1 and MICA loci. HLA-DP typing was further available. MICB98 mismatches were significantly associated with an increased incidence of acute (grade II-IV: HR, 1.20; 95% CI, 1.15 to 1.24; P < 0.001; grade III-IV: HR, 2.28; 95% CI, 1.56 to 3.34; P < 0.001) and chronic GVHD (HR, 1.21; 95% CI, 1.10 to 1.33; P < 0.001). MICB98 matching significantly reduced the effect of CMV status on overall mortality from a hazard ratio of 1.77 to 1.16. MICB98 mismatches showed a GVHD-independent association with a higher incidence of CMV infection/reactivation (HR, 1.84; 95% CI, 1.34 to 2.51; P < 0.001). Hence selecting a MICB98-matched donor significantly reduces the GVHD incidence and lowers the impact of CMV status on overall survival. more...
- Published
- 2020
- Full Text
- View/download PDF
19. Compatibility at amino acid position 98 of MICB reduces the incidence of graft-versus-host disease in conjunction with the CMV status
- Author
-
CDL Patiëntenzorg MI, Infection & Immunity, Cancer, Carapito, Raphael, Aouadi, Ismail, Pichot, Angélique, Spinnhirny, Perrine, Morlon, Aurore, Kotova, Irina, Macquin, Cécile, Rolli, Véronique, Cesbron, Anne, Gagne, Katia, Oudshoorn, Machteld, van der Holt, Bronno, Labalette, Myriam, Spierings, Eric, Picard, Christophe, Loiseau, Pascale, Tamouza, Ryad, Toubert, Antoine, Parissiadis, Anne, Dubois, Valérie, Paillard, Catherine, Maumy-Bertrand, Myriam, Bertrand, Frédéric, von dem Borne, Peter A, Kuball, Jürgen H E, Michallet, Mauricette, Lioure, Bruno, Peffault de Latour, Régis, Blaise, Didier, Cornelissen, Jan J, Yakoub-Agha, Ibrahim, Claas, Frans, Moreau, Philippe, Charron, Dominique, Mohty, Mohamad, Morishima, Yasuo, Socié, Gérard, Bahram, Seiamak, CDL Patiëntenzorg MI, Infection & Immunity, Cancer, Carapito, Raphael, Aouadi, Ismail, Pichot, Angélique, Spinnhirny, Perrine, Morlon, Aurore, Kotova, Irina, Macquin, Cécile, Rolli, Véronique, Cesbron, Anne, Gagne, Katia, Oudshoorn, Machteld, van der Holt, Bronno, Labalette, Myriam, Spierings, Eric, Picard, Christophe, Loiseau, Pascale, Tamouza, Ryad, Toubert, Antoine, Parissiadis, Anne, Dubois, Valérie, Paillard, Catherine, Maumy-Bertrand, Myriam, Bertrand, Frédéric, von dem Borne, Peter A, Kuball, Jürgen H E, Michallet, Mauricette, Lioure, Bruno, Peffault de Latour, Régis, Blaise, Didier, Cornelissen, Jan J, Yakoub-Agha, Ibrahim, Claas, Frans, Moreau, Philippe, Charron, Dominique, Mohty, Mohamad, Morishima, Yasuo, Socié, Gérard, and Bahram, Seiamak more...
- Published
- 2020
20. Matching for the nonconventional MHC-I MICA gene significantly reduces the incidence of acute and chronic GVHD
- Author
-
Christophe Picard, Cécile Macquin, Sergi Querol, Catherine Paillard, Katharina Fleischhauer, Gaëlle Giacometti, Bronno van der Holt, Ibrahim Yakoub-Agha, Wassila Ilias, Anne Cesbron, Myriam Labopin, Masao Ota, Jorge Sierra, Fabio Ciceri, Dominique Charron, Ryad Tamouza, Régis Peffault de Latour, Xavier Lafarge, Katia Gagne, Seiamak Bahram, Myriam Maumy-Bertrand, Meiggie Untrau, Pascale Loiseau, Raphael Carapito, Jürgen Kuball, Bruno Lioure, Frans H.J. Claas, Noel Milpied, Antoine Toubert, Jan J. Cornelissen, Irina Kotova, Philippe Moreau, Eric Spierings, Mauricette Michallet, Arnon Nagler, Annette Schmitt-Graeff, Angélique Pichot, Petya Apostolova, Mohamad Mohty, Aurore Morlon, Myriam Labalette, Nicolas Jung, Didier Blaise, Yoshihiko Katsuyama, Hidetoshi Inoko, A. Parissiadis, Frédéric Bertrand, Marius Kwemou, Sandra Michel, Machteld Oudshoorn, Gérard Socié, Robert Zeiser, Peter A. von dem Borne, Valérie Dubois, Luca Vago, Carapito, Raphael, Jung, Nicola, Kwemou, Mariu, Untrau, Meiggie, Michel, Sandra, Pichot, Angélique, Giacometti, Gaëlle, Macquin, Cécile, Ilias, Wassila, Morlon, Aurore, Kotova, Irina, Apostolova, Petya, Schmitt Graeff, Annette, Cesbron, Anne, Gagne, Katia, Oudshoorn, Machteld, Van Der Holt, Bronno, Labalette, Myriam, Spierings, Eric, Picard, Christophe, Loiseau, Pascale, Tamouza, Ryad, Toubert, Antoine, Parissiadis, Anne, Dubois, Valérie, Lafarge, Xavier, Maumy Bertrand, Myriam, Bertrand, Frédéric, Vago, Luca, Ciceri, Fabio, Paillard, Catherine, Querol, Sergi, Sierra, Jorge, Fleischhauer, Katharina, Nagler, Arnon, Labopin, Myriam, Inoko, Hidetoshi, Von Dem Borne, Peter A., Kuball, Jürgen, Ota, Masao, Katsuyama, Yoshihiko, Michallet, Mauricette, Lioure, Bruno, De Latour, Régis Peffault, Blaise, Didier, Cornelissen, Jan J., Yakoub Agha, Ibrahim, Claas, Fran, Moreau, Philippe, Milpied, Noël, Charron, Dominique, Mohty, Mohamad, Zeiser, Robert, Socié, Gérard, Bahram, Seiamak, inconnu, Inconnu, Institut de Recherche Mathématique Avancée (IRMA), Université de Strasbourg (UNISTRA)-Centre National de la Recherche Scientifique (CNRS), Immuno-Rhumatologie Moléculaire, Université de Strasbourg (UNISTRA)-Institut National de la Santé et de la Recherche Médicale (INSERM), Laboratoire de Mathématiques et Modélisation d'Evry (LaMME), Institut National de la Recherche Agronomique (INRA)-Université d'Évry-Val-d'Essonne (UEVE)-Centre National de la Recherche Scientifique (CNRS), laboratoire d'Etudes et de recherches en Statistiques et Développement (LERSTAD), Université Gaston Bergé Sénégal, Laboratoire d'Acoustique Environnementale (IFSTTAR/AME/LAE), Institut Français des Sciences et Technologies des Transports, de l'Aménagement et des Réseaux (IFSTTAR)-Université de Lyon-PRES Université Nantes Angers Le Mans (UNAM), Physique des interactions ioniques et moléculaires (PIIM), Aix Marseille Université (AMU)-Centre National de la Recherche Scientifique (CNRS), LabEx Transplantex [Strasbourg], Université de Strasbourg (UNISTRA), Etablissement Français du Sang [Nantes], Etablissement Français du Sang - Alpes-Méditerranée (EFS - Alpes-Méditerranée), Etablissement Français du Sang, Service de pneumologie [Rennes] = Pneumology [Rennes], CHU Pontchaillou [Rennes], Anthropologie bio-culturelle, Droit, Ethique et Santé (ADES), Aix Marseille Université (AMU)-EFS ALPES MEDITERRANEE-Centre National de la Recherche Scientifique (CNRS), Alloimmunité-Autoimmunité-Transplantation (A2T), Institut Universitaire d'Hématologie (IUH), Université Paris Diderot - Paris 7 (UPD7)-Université Paris Diderot - Paris 7 (UPD7)-Institut National de la Santé et de la Recherche Médicale (INSERM), Hématologie -Immunologie -Cibles thérapeutiques, Université Paris Diderot - Paris 7 (UPD7)-Institut National de la Santé et de la Recherche Médicale (INSERM), Hôpital Saint-Louis, Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Université Paris Diderot - Paris 7 (UPD7), Sociétés, Acteurs, Gouvernement en Europe (SAGE), Politique, Religion, Institutions et Sociétés : Mutations Européennes - Groupe de Sociologie Politique Européenne (PRISME-GSPE), Centre National de la Recherche Scientifique (CNRS), Centre de Transfusion Sanguine Aquitaine-Limousin (CTS AQUITAINE-LIMOUSIN), Centre de Transfusion Sanguine, Ospedale San Raffaele, Université Pierre et Marie Curie - Paris 6 - UFR de Médecine Pierre et Marie Curie (UPMC), Université Pierre et Marie Curie - Paris 6 (UPMC), Barcelona Cord Blood Bank, Agrosystèmes tropicaux (ASTRO), Institut National de la Recherche Agronomique (INRA), Chaim Sheba Medical Center [Ramat Gan, Israel], CHU Saint-Antoine [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Hôpital Edouard Herriot [CHU - HCL], Hospices Civils de Lyon (HCL), Département d'Oncologie et Hématologie [Strasbourg], Les Hôpitaux Universitaires de Strasbourg (HUS), Université Paris Diderot - Paris 7 (UPD7), Erasmus University Medical Center [Rotterdam] (Erasmus MC), Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille), Department of Immunohematology and Blood Transfusion, Leiden University Medical Center (LUMC), Universiteit Leiden-Universiteit Leiden, Centre hospitalier universitaire de Nantes (CHU Nantes), Centre d'Investigations Biomédicales-Hématologie, Oncologie et Greffes (CIB-HOG), Hôpital St Louis, Assistance Publique des Hôpitaux de Paris (AP-HP), Centre d'Investigations Biomédicales-Hématologie, Institut National de la Recherche Agronomique (INRA)-Université d'Évry-Val-d'Essonne (UEVE)-ENSIIE-Centre National de la Recherche Scientifique (CNRS), Service de pneumologie, Université de Rennes 1 (UR1), Université de Rennes (UNIV-RENNES)-Université de Rennes (UNIV-RENNES)-CHU Pontchaillou [Rennes], Assistance publique - Hôpitaux de Paris (AP-HP) (APHP)-Université Paris Diderot - Paris 7 (UPD7), Centre National de la Recherche Scientifique (CNRS)-Université de Strasbourg (UNISTRA), ALWP-EBMT & Département d'hématologie et de thérapie cellulaire [AP-HP Hôpital Saint-Antoine], AP-HP - Hôpital Saint-Antoine, Hematology, Institut de Recherche Mathématique Avancée ( IRMA ), Université de Strasbourg ( UNISTRA ) -Centre National de la Recherche Scientifique ( CNRS ), Université de Strasbourg ( UNISTRA ) -Institut National de la Santé et de la Recherche Médicale ( INSERM ), Laboratoire de Mathématiques et Modélisation d'Evry ( LaMME ), Institut National de la Recherche Agronomique ( INRA ) -Université d'Évry-Val-d'Essonne ( UEVE ) -ENSIIE-Centre National de la Recherche Scientifique ( CNRS ), laboratoire d'Etudes et de recherches en Statistiques et Développement ( LERSTAD ), Laboratoire d'Acoustique Environnementale ( IFSTTAR/AME/LAE ), Institut Français des Sciences et Technologies des Transports, de l'Aménagement et des Réseaux ( IFSTTAR ) -Université de Lyon-PRES Université Nantes Angers Le Mans ( UNAM ), Laboratoire d'Histoire des Sciences et de Philosophie - Archives Henri Poincaré ( LHSP ), Université de Lorraine ( UL ) -Centre National de la Recherche Scientifique ( CNRS ), Physique des interactions ioniques et moléculaires ( PIIM ), Aix Marseille Université ( AMU ) -Centre National de la Recherche Scientifique ( CNRS ), Functional Genomics and Cancer, Etablissement Français du Sang - Alpes-Méditerranée ( EFS - Alpes-Méditerranée ), Université de Rennes 1 ( UR1 ), Université de Rennes ( UNIV-RENNES ) -Université de Rennes ( UNIV-RENNES ) -CHU Pontchaillou [Rennes], Anthropologie bio-culturelle, Droit, Ethique et Santé ( ADES ), Aix Marseille Université ( AMU ) -EFS ALPES MEDITERRANEE-Centre National de la Recherche Scientifique ( CNRS ), Alloimmunité-Autoimmunité-Transplantation ( A2T ), Université Paris Diderot - Paris 7 ( UPD7 ) -Institut National de la Santé et de la Recherche Médicale ( INSERM ), Assistance publique - Hôpitaux de Paris (AP-HP)-Université Paris Diderot - Paris 7 ( UPD7 ), Sociétés, Acteurs, Gouvernement en Europe ( SAGE ), Politique, Religion, Institutions et Sociétés : Mutations Européennes - Groupe de Sociologie Politique Européenne ( PRISME-GSPE ), Centre National de la Recherche Scientifique ( CNRS ), Centre de Transfusion Sanguine Aquitaine-Limousin ( CTS AQUITAINE-LIMOUSIN ), Géographie de l'environnement ( GEODE ), Centre National de la Recherche Scientifique ( CNRS ) -Université Toulouse - Jean Jaurès ( UT2J ), Université Pierre et Marie Curie - Paris 6 - UFR de Médecine Pierre et Marie Curie ( UPMC ), Université Pierre et Marie Curie - Paris 6 ( UPMC ), Agrosystèmes tropicaux ( ASTRO ), Institut National de la Recherche Agronomique ( INRA ), Hospices Civils de Lyon ( HCL ), IFR Saint-Louis, institut d'hématologie ( ISLIH ), Commissariat à l'énergie atomique et aux énergies alternatives ( CEA ) -Assistance publique - Hôpitaux de Paris (AP-HP)-Université Paris Diderot - Paris 7 ( UPD7 ) -Institut National de la Santé et de la Recherche Médicale ( INSERM ) -Centre National de la Recherche Scientifique ( CNRS ), Erasmus MC University medical Centre / Daniel den Hoed Cancer centre, Centre Hospitalier Régional Universitaire [Lille] ( CHRU Lille ), Centre hospitalier universitaire de Nantes ( CHU Nantes ), Laboratoire de Mathématiques et Modélisation d'Evry, PRES Université Nantes Angers Le Mans (UNAM)-Université de Lyon-Institut Français des Sciences et Technologies des Transports, de l'Aménagement et des Réseaux (IFSTTAR), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université, Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Strasbourg (UNISTRA), Centre National de la Recherche Scientifique (CNRS)-ENSIIE-Université d'Évry-Val-d'Essonne (UEVE)-Institut National de la Recherche Agronomique (INRA), Institut National de la Santé et de la Recherche Médicale (INSERM)-Institut Universitaire d'Hématologie (IUH), Université Paris Diderot - Paris 7 (UPD7)-Université Paris Diderot - Paris 7 (UPD7), Université Paris Diderot - Paris 7 (UPD7)-Assistance publique - Hôpitaux de Paris (AP-HP) (APHP), and Université Paris Diderot - Paris 7 (UPD7)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP) more...
- Subjects
0301 basic medicine ,Male ,medicine.medical_treatment ,[SDV]Life Sciences [q-bio] ,Medizin ,Graft vs Host Disease ,Hematopoietic stem cell transplantation ,Biochemistry ,Linkage Disequilibrium ,immune system diseases ,HLA Antigens ,Cytotoxic T cell ,Child ,ComputingMilieux_MISCELLANEOUS ,HLA-DQB1 ,biology ,Histocompatibility Testing ,Incidence ,Hematopoietic Stem Cell Transplantation ,Hematology ,Middle Aged ,Allografts ,3. Good health ,surgical procedures, operative ,NK Cell Lectin-Like Receptor Subfamily K ,Child, Preschool ,Acute Disease ,[SDV.IMM]Life Sciences [q-bio]/Immunology ,Female ,Adult ,Adolescent ,Immunology ,Human leukocyte antigen ,03 medical and health sciences ,MHC class I ,medicine ,Journal Article ,Humans ,Aged ,Retrospective Studies ,Transplantation ,[ SDV ] Life Sciences [q-bio] ,Histocompatibility Antigens Class I ,Infant, Newborn ,Infant ,Cell Biology ,medicine.disease ,Histocompatibility ,stomatognathic diseases ,030104 developmental biology ,Graft-versus-host disease ,Chronic Disease ,biology.protein - Abstract
Graft-versus-host disease (GVHD) is among the most challenging complications in unrelated donor hematopoietic cell transplantation (HCT). The highly polymorphic MHC class I chain-related gene A, MICA, encodes a stress-induced glycoprotein expressed primarily on epithelia. MICA interacts with the invariant activating receptor NKG2D, expressed by cytotoxic lymphocytes, and is located in the MHC, next to HLA-B. Hence, MICA has the requisite attributes of a bona fide transplantation antigen. Using high-resolution sequence-based genotyping of MICA, we retrospectively analyzed the clinical effect of MICA mismatches in a multicenter cohort of 922 unrelated donor HLA-A, HLA-B, HLA-C, HLA-DRB1, and HLA-DQB1 10/10 allele-matched HCT pairs. Among the 922 pairs, 113 (12.3%) were mismatched in MICA. MICA mismatches were significantly associated with an increased incidence of grade III-IV acute GVHD (hazard ratio [HR], 1.83; 95% confidence interval [CI], 1.50-2.23; P < .001), chronic GVHD (HR, 1.50; 95% CI, 1.45-1.55; P < .001), and nonelapse mortality (HR, 1.35; 95% CI, 1.24-1.46; P < .001). The increased risk for GVHD was mirrored by a lower risk for relapse (HR, 0.50; 95% CI, 0.43-0.59; P < .001), indicating a possible graft-versus-leukemia effect. In conclusion, when possible, selecting a MICA-matched donor significantly influences key clinical outcomes of HCT in which a marked reduction of GVHD is paramount. The tight linkage disequilibrium between MICA and HLA-B renders identifying a MICA-matched donor readily feasible in clinical practice. more...
- Published
- 2016
- Full Text
- View/download PDF
21. WHAT IMMUNOSUPPRESSIVE TREATMENT SHOULD ONE ENVISAGE WHEN TRANSPLANTECTOMY HAS TO BE CARRIED OUT IMMEDIATELY AFTER TRANSPLANTATION?: CC-015
- Author
-
Parissiadis, Anne, Froelich, Nadine, Renner, Véronique, Moulin, Bruno, Hanau, Daniel, and Caillard, Sophie
- Published
- 2011
22. Evidence for Humoral Rejection of a Pancreatic Islet Graft and Rescue with Rituximab and IV Immunoglobulin Therapy
- Author
-
Kessler, L., Parissiadis, A., Bayle, F., Moreau, F., Pinget, M., Froelich, N., Cazenave, J.-P., Berney, T., Benhamou, P. Y., and Hanau, D.
- Published
- 2009
- Full Text
- View/download PDF
23. Incidence of anti-mica antibodies in kidney transplant recipients: P-241
- Author
-
Parissiadis, A, Caillard, S, Froelich, N, Marbach, N, Moulin, B, Cazenave, J-P, and Hanau, D
- Published
- 2007
24. Unilateral necrotising toxoplasmic retinochoroiditis as the main clinical manifestation of a peptide transporter (TAP) deficiency
- Author
-
Parissiadis, A, Dormoy, A, Fricker, D, Hanau, D, de la Salle, H, Cazenave, J-P, Lenoble, P, and Donato, L
- Published
- 2005
25. Second HLA-A☆68 null allele, A☆6818 N, identified
- Author
-
Dormoy, A., Froelich, N., Parissiadis, A., Cazenave, J.-P, and Tongio, M. M.
- Published
- 2002
26. A null HLA-A*68 allele in a bone marrow donor
- Author
-
Laforet, M., Froelich, N., Parissiadis, A., Schell, A., Pfeiffer, B., Cazenave, J.-P., and Tongio, M. M.
- Published
- 1999
27. Prognostic Value of the Persistence of C1q-Binding Anti-HLA Antibodies in Acute Antibody-Mediated Rejection in Kidney Transplantation
- Author
-
Valérie Chabot, Gilles Blancho, Raj Purgus, A. Parissiadis, Barbara Proust, Christiane Mousson, Moglie Le Quintrec, Philippe Grimbert, Matthias Büchler, Philippe Gatault, Paolo Malvezzi, Johnny Sayegh, Vincent Vuiblet, Valérie Chatelet, Yvon Lebranchu, Gwendaline Guidicelli, Isabelle Top, Frédéric Dehaut, Dany Anglicheau, Jérôme Tourret, Emmanuel Morelon, Elodie Bailly, Pierre François Westeel, CHU Trousseau [Tours], Centre Hospitalier Régional Universitaire de Tours (CHRU Tours), Université Francois Rabelais [Tours], Institut Necker Enfants-Malades (INEM - UM 111 (UMR 8253 / U1151)), Université Paris Descartes - Paris 5 (UPD5)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Institut de transplantation urologie-néphrologie (ITUN), Université de Nantes (UN)-Centre hospitalier universitaire de Nantes (CHU Nantes), Centre Hospitalier Universitaire de Reims (CHU Reims), Service de Néphrologie-Dialyse-Transplantation rénale [CHU Caen], Université de Caen Normandie (UNICAEN), Normandie Université (NU)-Normandie Université (NU)-CHU Caen, Normandie Université (NU)-Tumorothèque de Caen Basse-Normandie (TCBN)-Tumorothèque de Caen Basse-Normandie (TCBN), CIC CHU Lyon (inserm), Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Institut National de la Santé et de la Recherche Médicale (INSERM), CHU Grenoble, Université Joseph Fourier - Grenoble 1 (UJF)-CHU Grenoble, Etablissement Français du Sang - Grand Est (EFS - alsace strasbourg), Service de Néphrologie [CHU Pitié-Salpêtrière], CHU Pitié-Salpêtrière [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), CHU de Bordeaux Pellegrin [Bordeaux], Centre Hospitalier Universitaire d'Angers (CHU Angers), PRES Université Nantes Angers Le Mans (UNAM), Service de néphrologie (CHU de Dijon), Centre Hospitalier Universitaire de Dijon - Hôpital François Mitterrand (CHU Dijon), Institut Mondor de Recherche Biomédicale (IMRB), Institut National de la Santé et de la Recherche Médicale (INSERM)-IFR10-Université Paris-Est Créteil Val-de-Marne - Paris 12 (UPEC UP12), CHU Lille, Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier), Cellules Souches, Plasticité Cellulaire, Médecine Régénératrice et Immunothérapies (IRMB), Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Montpellier (UM), CHU Marseille, CHU Amiens-Picardie, CHU Caen, Normandie Université (NU)-Tumorothèque de Caen Basse-Normandie (TCBN), Université de Montpellier (UM)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier), and Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris-Est Créteil Val-de-Marne - Paris 12 (UPEC UP12)-IFR10 more...
- Subjects
Graft Rejection ,Male ,Time Factors ,[SDV]Life Sciences [q-bio] ,030232 urology & nephrology ,030230 surgery ,Gastroenterology ,0302 clinical medicine ,HLA Antigens ,Isoantibodies ,Risk Factors ,Kidney transplantation ,ComputingMilieux_MISCELLANEOUS ,Plasma Exchange ,biology ,Graft Survival ,Immunoglobulins, Intravenous ,Middle Aged ,3. Good health ,Treatment Outcome ,Predictive value of tests ,Female ,Rituximab ,France ,Antibody ,Immunosuppressive Agents ,Protein Binding ,medicine.drug ,Adult ,medicine.medical_specialty ,Placebo ,03 medical and health sciences ,Predictive Value of Tests ,Glomerulopathy ,Internal medicine ,Complement C4b ,medicine ,Humans ,Aged ,Transplantation ,business.industry ,Complement C1q ,Transplant glomerulopathy ,medicine.disease ,Kidney Transplantation ,Peptide Fragments ,biology.protein ,business - Abstract
International audience; Background: The differential pathogenicity of anti-HLA donor-specific antibodies (DSAs) is not fully understood. The presence of complement-binding DSAs helps in better defining the prognosis of acute antibody-mediated rejection (ABMR). The evolution of these antibodies after the treatment of ABMR is unknown.Methods: We included patients from the French multicenter RITUX ERAH study diagnosed with acute ABMR within the first year of renal transplantation, with circulating anti-HLA DSAs and treated randomly by rituximab or placebo (and intravenous immunoglobulins, plasma exchange). We centrally analyzed serum samples at the time of ABMR, 3 and 6 months after ABMR, with anti-HLA DSAs specificities and C1q-binding capacity assessment.Results: Twenty-five patients were included: 68% had C1q-binding DSAs at the time of ABMR. The presence of C1q-binding DSAs was associated with a poorer evolution of chronic glomerulopathy at 6 months (P = 0.036). The persistence of C1q-binding DSAs at 3 and/or 6 months after ABMR was associated with more severe chronic glomerulopathy (P = 0.006), greater C4d score deposition score at 6 months after ABMR (P = 0.008), and graft loss 5 years after ABMR (P = 0.029). C1q-binding capacity was associated with the DSA MFI but 5 C1q-binding DSAs in 4 patients had low MFI values without a prozone effect.Conclusion: The presence and persistence of anti-HLA C1q-binding DSAs after ABMR is a detrimental marker, leading to transplant glomerulopathy and graft loss. Assessment of the complement-binding capacities of DSAs could help decide treatment intensification. more...
- Published
- 2018
- Full Text
- View/download PDF
28. HLA-DRB3/4/5 mismatches are associated with increased risk of acute GVHD in 10/10 matched unrelated donor hematopoietic cell transplantation
- Author
-
Virginie Moalic, A. Parissiadis, Mauricette Michallet, Matthieu Filloux, Florent Delbos, Marie-Thérèse Rubio, Edouard Forcade, Patrice Chevallier, A. Dormoy, Xavier Lafarge, Virginie Renac, Anne Cesbron, Béatrice Pédron, Christophe Picard, Pascale Loiseau, Abdelali Boudifa, Kahina Amokrane, Federico Garnier, F Quainon, Dominique Masson, Peter van Endert, Françoise Hau, M Fort, Raphaël Porcher, Ibrahim Yakoub-Agha, Valérie Dubois, Isabelle Jollet, Julie Bonneau, Etienne Daguindau, Natacha Maillard, Gérard Socié, Anne Kennel, Jacques-Olivier Bay, Anne Devys, Erwann Quelvennec, Régis Peffault de Latour, Stéphanie Ducreux, Myriam Labalette, Claude-Eric Bulabois, Muriel De Matteis, Etablissement français du sang - Auvergne-Rhône-Alpes (EFS), Hôpital Saint-Louis, Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Université Paris Diderot - Paris 7 (UPD7), Service de neurophysiologie clinique (CHRU Lille), Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille), Laboratoire d'Immunologie (EA 2686), Université de Lille, Droit et Santé, Service d'hématologie [Hôpital Edouard Herriot - HCL], Hôpital Edouard Herriot [CHU - HCL], Hospices Civils de Lyon (HCL)-Hospices Civils de Lyon (HCL), Service d'Hématologie [CHRU Nancy], Centre Hospitalier Régional Universitaire de Nancy (CHRU Nancy), Composantes innées de la réponse immunitaire et différenciation (CIRID), Université Bordeaux Segalen - Bordeaux 2-Centre National de la Recherche Scientifique (CNRS), Département de cancérologie et d'hématologie, CHU Grenoble-Hôpital Michallon, Service d'hématologie, Centre Hospitalier Régional Universitaire de Besançon (CHRU Besançon), Etablissement français du sang [Angers], Laboratoire de Génétique Moléculaire et d'Histocompatibilité [Brest], Hôpital Morvan [Brest]-Centre Hospitalier Régional Universitaire de Brest (CHRU Brest), Etablissement français du sang - Normandie (EFS), CHU Pitié-Salpêtrière [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Anthropologie bio-culturelle, Droit, Ethique et Santé (ADES), Aix Marseille Université (AMU)-EFS ALPES MEDITERRANEE-Centre National de la Recherche Scientifique (CNRS), Diabète de Type 1 : mécanismes et traitements immunologiques, Université Paris Descartes - Paris 5 (UPD5)-Institut National de la Santé et de la Recherche Médicale (INSERM), Laboratoire d'histocompatibilité et d'immunogénétique [Angers], Université d'Angers (UA), Développement du Systeme Immunitaire, Université Paris Descartes - Paris 5 (UPD5)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Contrôle de la Réponse Immune B et des Lymphoproliférations (CRIBL), Université de Limoges (UNILIM)-Génomique, Environnement, Immunité, Santé, Thérapeutique (GEIST FR CNRS 3503)-Centre National de la Recherche Scientifique (CNRS), AP-HP Hôpital universitaire Robert-Debré [Paris], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Laboratoire de Biologie Médicale [Rennes], Etablissement français du sang [Rennes] (EFS Bretagne), Etablissement Français du Sang - Grand Est (EFS - alsace strasbourg), CHU Toulouse [Toulouse], Etablissement français du sang [Bourgogne-Franche-Comté] (EFS [Bourgogne-Franche-Comté]), Centre hospitalier universitaire de Poitiers (CHU Poitiers), Etablissement français du sang [Poitiers] (EFS), Centre hospitalier universitaire de Nantes (CHU Nantes), Etablissement Français du Sang [Nantes], CHU Clermont-Ferrand, Etablissement français du sang [Clermont-Ferrand] (EFS), Agence de la biomédecine [Saint-Denis la Plaine], Hopital Saint-Louis [AP-HP] (AP-HP), Immunogénétique humaine, Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Institut National de la Santé et de la Recherche Médicale (INSERM), Département d'épidémiologie, biostatistique et recherche clinique, Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-AP-HP - Hôpital Bichat - Claude Bernard [Paris], Institut Universitaire d'Hématologie (IUH), Université Paris Diderot - Paris 7 (UPD7), Centre Hospitalier Universitaire de Toulouse (CHU Toulouse), Etablissement français du sang [Bourgogne-Franche-Comté] (EFS BFC), Université Paris Diderot - Paris 7 (UPD7)-Assistance publique - Hôpitaux de Paris (AP-HP) (APHP), Centre Hospitalier Régional Universitaire [Besançon] (CHRU Besançon)-Hôpital Jean Minjoz, CHU Pitié-Salpêtrière [APHP], Centre National de la Recherche Scientifique (CNRS)-Université de Limoges (UNILIM)-Génomique, Environnement, Immunité, Santé, Thérapeutique (GEIST FR CNRS 3503), Etablissement français du sang [Bourgogne-France-Comté] (EFS [Bourgogne-France-Comté]), CHU Saint Louis [APHP], Assistance publique - Hôpitaux de Paris (AP-HP) (APHP)-Institut National de la Santé et de la Recherche Médicale (INSERM), and Assistance publique - Hôpitaux de Paris (AP-HP) (APHP)-AP-HP - Hôpital Bichat - Claude Bernard [Paris] more...
- Subjects
Oncology ,medicine.medical_specialty ,Hematopoietic cell ,business.industry ,[SDV]Life Sciences [q-bio] ,Hazard ratio ,Hematology ,Disease ,Matched Unrelated Donor ,3. Good health ,Transplantation ,03 medical and health sciences ,0302 clinical medicine ,Increased risk ,Unrelated Donor ,030220 oncology & carcinogenesis ,Internal medicine ,medicine ,business ,030215 immunology ,HLA-DRB3 - Abstract
International audience; Matching for HLA‐A, ‐B, ‐C, and ‐DRB1 loci (8/8 match) is currently the gold standard for unrelated donor hematopoietic cell transplantation (HCT). In Europe, patients are also matched at the HLA‐DQB1 loci (10/10 match). However, there is increasing evidence that matching at HLA‐DRB3/4/5 loci may help to lower transplant‐related morbidity and mortality. We therefore investigated the impact of HLA‐DRB3/4/5 mismatches on outcomes in 1975 patients who received a first 10/10 matched unrelated donor (MUD) HCT in France from 2000 to 2012 for a hematological malignancy. High‐resolution typing was performed at HLA‐A, ‐B, ‐C, ‐DRB1, ‐DQB1, ‐DPB1, and ‐DRB3/4/5 loci for all donor/recipient pairs. Compared with DRB3/4/5‐matched pairs, patients who received a MUD HCT from a DRB3/4/5 mismatched donor had a significantly increased risk of grade II‐IV acute graft‐versus‐host disease (aGVHD) (Adjusted Hazard Ratio (HR) 1.43 (1.07 to 1.90)) associated with lower graft‐versus‐host disease‐free and relapse‐free survival (GRFS) (Adjusted HR 1.20 (1.02 to 1.42)). Conversely, we observed no differences in terms of chronic GVHD, nonrelapse mortality, relapse and overall survival. However, we believe that patients stand to benefit from DRB3/4/5 loci being considered for unrelated donor selection to improve GRFS and then quality of life after unrelated HCT. more...
- Published
- 2018
- Full Text
- View/download PDF
29. Does a Useful Test Exist to Properly Evaluate the Pathogenicity of Donor-specific Antibodies? Lessons From a Comprehensive Analysis in a Well-studied Single-center Kidney Transplant Cohort
- Author
-
Gautier Vargas, Gabriela, primary, Olagne, Jérome, additional, Parissiadis, Anne, additional, Joly, Mélanie, additional, Cognard, Noelle, additional, Perrin, Peggy, additional, Froelich, Nadine, additional, Guntz, Philippe, additional, Gachet, Christian, additional, Moulin, Bruno, additional, and Caillard, Sophie, additional more...
- Published
- 2019
- Full Text
- View/download PDF
30. Incidence of Specific Class II Antibodies after Kidney Graft Loss
- Author
-
Parissiadis, A., Woehl-Jaegle, M. L., Meyer, C., Wolf, P., Tongio, M. M., Touraine, J. L., editor, Traeger, J., editor, Bétuel, H., editor, Dubernard, J. M., editor, Revillard, J. P., editor, and Dupuy, C., editor more...
- Published
- 1997
- Full Text
- View/download PDF
31. COMPARISON OF ELISA QUIKSCREEN® WITH CYTOTOXICITY FOR HLA CLASS I ANTIBODY DETECTION : A FRENCH NATIONAL COLLABORATIVE STUDY
- Author
-
PARISSIADIS, A., ABSI, L., ALCALAY, D., BIGNON, J. D., CESBRON, A., COHEN, J. M., COUSSEDIERE, C., DINE, G., FAILLE, N., FIZET, D., GEBUHRER, L., GRIVEAU, A. M., JOLLET, J., MASSON, D., PERRIER, P., SCHUHMACHER, A., and TONGIO, M. M. more...
- Published
- 1998
32. NUCLEOTIDE MUTATIONS IN EXON 1 ARE RESPONSIBLE FOR THE ABSENCE OF EXPRESSION OF A NEW HLA-A*68 ALLELE
- Author
-
LAFORET, M., FROELICH, N., PFEIFFER, B., SCHELL, A., PARISSIADIS, A., CAZENAVE, J.-P., and TONGIO, M. M.
- Published
- 1998
33. A nucleotide insertion in exon 4 is responsible for the absence of expression of an HLA-A *01 allele
- Author
-
Laforet, M., Froelich, N., Parissiadis, A., Pfeiffer, B., Schell, A., Faller, B., Woehl-Jaegle, M.-L., Cazenave, J.-P., and Tongio, M.-M.
- Published
- 1997
34. An intronic mutation responsible for a low level of expression of an HLA-A*24 allele
- Author
-
Laforet, M., Froelich, N., Parissiadis, A., Bausinger, H., Pfeiffer, B., and Tongio, M.-M.
- Published
- 1997
35. Anti-donor HLA antibody response after pancreatic islet grafting: characteristics, risk factors and impact on graft function
- Author
-
E, Pouliquen, P, Baltzinger, A, Lemle, Cc, Chen, A, Parissiadis, S, Borot, L, Frimat, S, Girerd, T, Berney, Cornali Lablanche, Sandrine, Benhamou, P.Y., E, Morelon, L, Badet, V, Dubois, L, Kessler, O, Thaunat, Laboratory of Fundamental and Applied Bioenergetics = Laboratoire de bioénergétique fondamentale et appliquée (LBFA), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Grenoble Alpes [2016-2019] (UGA [2016-2019]), Centre Hospitalier Universitaire [Grenoble] (CHU), and CHU Grenoble more...
- Subjects
[SDV]Life Sciences [q-bio] ,ComputingMilieux_MISCELLANEOUS ,[SDV.MHEP]Life Sciences [q-bio]/Human health and pathology - Abstract
International audience
- Published
- 2017
36. Prognostic Value of the Persistence of C1q-Binding Anti-HLA Antibodies in Acute Antibody-Mediated Rejection in Kidney Transplantation
- Author
-
Bailly, Elodie, primary, Anglicheau, Dany, additional, Blancho, Gilles, additional, Gatault, Philippe, additional, Vuiblet, Vincent, additional, Chatelet, Valérie, additional, Morelon, Emmanuel, additional, Malvezzi, Paolo, additional, Parissiadis, Anne, additional, Tourret, Jérôme, additional, Guidicelli, Gwendaline, additional, Sayegh, Johnny, additional, Mousson, Christiane, additional, Grimbert, Philippe, additional, Top, Isabelle, additional, Le Quintrec, Moglie, additional, Purgus, Raj, additional, Westeel, Pierre François, additional, Proust, Barbara, additional, Chabot, Valérie, additional, Lebranchu, Yvon, additional, Dehaut, Frédéric, additional, and Büchler, Matthias, additional more...
- Published
- 2018
- Full Text
- View/download PDF
37. Impact of KIR/HLA genetic combinations on double umbilical cord blood transplantation outcomes. Results of a French multicentric retrospective study on behalf of the Société Francophone de Greffe de Moelle et de Thérapie Cellulaire (SFGM-TC) and the Société Francophone d'Histocompatibilité et d'Immunogénétique (SFHI)
- Author
-
F Quainon, Evelyne Marry, C Retière, J.-F. Eliaou, A. Parissiadis, O Avinens, A Boudifa, Dominique Masson, N Legrand, Nicole Raus, Ibrahim Yakoub-Agha, A Batho, P Rettman, Florent Delbos, David Senitzer, Anne Kennel, A. Dormoy, Xavier Lafarge, Anne Devys, L. Absi, I Theodorou, M de Matteis, Anne Cesbron, M Drouet, Pascale Loiseau, Florent Malard, M Fort, Katia Gagne, Christophe Picard, Immunovirologie et polymorphisme génétique, Université de Nantes - UFR de Médecine et des Techniques Médicales (UFR MEDECINE), Université de Nantes (UN)-Université de Nantes (UN), Centre hospitalier universitaire de Nantes (CHU Nantes), Centre de Recherche Saint-Antoine (CRSA), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Sorbonne Université (SU), ArcelorMittal Maizières Research SA, ArcelorMittal, Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier), Institut de Recherche en Cancérologie de Montpellier (IRCM - U1194 Inserm - UM), CRLCC Val d'Aurelle - Paul Lamarque-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Montpellier (UM), Anthropologie bio-culturelle, Droit, Ethique et Santé (ADES), Aix Marseille Université (AMU)-EFS ALPES MEDITERRANEE-Centre National de la Recherche Scientifique (CNRS), Etablissement Français du Sang - Alpes-Méditerranée (EFS - Alpes-Méditerranée), Etablissement Français du Sang, Etablissement français du sang [Bourgogne-Franche-Comté] (EFS BFC), Etablissement Français du Sang Nouvelle Aquitaine [Bordeaux] (EFS Bordeaux Nouvelle Aquitaine), Etablissement français du sang [Nice] (EFS), Centre Hospitalier Régional Universitaire de Nancy (CHRU Nancy), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Laboratoire Paul Painlevé (LPP), Université de Lille-Centre National de la Recherche Scientifique (CNRS), Groupe Immunité des Muqueuses et Agents Pathogènes (GIMAP), Université Jean Monnet - Saint-Étienne (UJM), Etablissement français du sang [Clermont-Ferrand] (EFS), Centre d'Immunologie et de Maladies Infectieuses (CIMI), Université Pierre et Marie Curie - Paris 6 (UPMC)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Etablissement français du sang [Caen], Ambiances, Architectures, Urbanités (AAU ), École Centrale de Nantes (ECN)-École nationale supérieure d'architecture de Nantes (ENSA Nantes)-École nationale supérieure d'architecture de Grenoble (ENSAG)-Ministère de la Culture et de la Communication (MCC)-Centre National de la Recherche Scientifique (CNRS), Etablissement Français du Sang - Grand Est (EFS - alsace strasbourg), Développement du Systeme Immunitaire, Université Paris Descartes - Paris 5 (UPD5)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), CHU Limoges, City of Hope National Medical Center, Registre France Greffe de Moelle [Saint-Denis La Plaine] (RFGM), Agence de la biomédecine [Saint-Denis la Plaine], Service d'hématologie [Hôpital Edouard Herriot - HCL], Hôpital Edouard Herriot [CHU - HCL], Hospices Civils de Lyon (HCL)-Hospices Civils de Lyon (HCL), Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille), Etablissement Français du Sang [Nantes], Biologie des Organismes et Ecosystèmes Aquatiques (BOREA), Université de Caen Normandie (UNICAEN), Normandie Université (NU)-Normandie Université (NU)-Muséum national d'Histoire naturelle (MNHN)-Institut de Recherche pour le Développement (IRD)-Sorbonne Université (SU)-Centre National de la Recherche Scientifique (CNRS)-Université des Antilles (UA), Arcelor Research S.A, Arcelor, Laboratoire d'Immunologie, CHU Saint-Eloi, Anthropologie bio-culturelle, Droit, Ethique et Santé ( ADES ), Aix Marseille Université ( AMU ) -EFS ALPES MEDITERRANEE-Centre National de la Recherche Scientifique ( CNRS ), Etablissement Français du Sang - Alpes-Méditerranée ( EFS - Alpes-Méditerranée ), Etablissement français du sang [Besançon] ( EFS ), Centre de Transfusion Sanguine Aquitaine-Limousin ( CTS AQUITAINE-LIMOUSIN ), Centre de Transfusion Sanguine, Etablissement français du sang [Nice] ( EFS ), Laboratoire Paul Painlevé - UMR 8524 ( LPP ), Université de Lille-Centre National de la Recherche Scientifique ( CNRS ), Groupe Immunité des Muqueuses et Agents Pathogènes ( GIMAP ), Université Jean Monnet [Saint-Étienne] ( UJM ), Centre d'Immunologie et de Maladies Infectieuses ( CIMI ), Université Pierre et Marie Curie - Paris 6 ( UPMC ) -Institut National de la Santé et de la Recherche Médicale ( INSERM ) -Centre National de la Recherche Scientifique ( CNRS ), Ambiances architecturales et urbaines ( AAU ), Ministère de la Culture et de la Communication ( MCC ) -École nationale supérieure d'architecture de Grenoble ( ENSAG ) -École nationale supérieure d'architecture de Nantes ( ENSA Nantes ) -École Centrale de Nantes ( ECN ) -Centre National de la Recherche Scientifique ( CNRS ), Université Paris Descartes - Paris 5 ( UPD5 ) -Institut National de la Santé et de la Recherche Médicale ( INSERM ) -Centre National de la Recherche Scientifique ( CNRS ), Laboratoire d'allergologie, Centre Hospitalier Universitaire d'Angers, Registre France Greffe de Moelle [Saint-Denis La Plaine] ( RFGM ), Hospices Civils de Lyon ( HCL ) -Hospices Civils de Lyon ( HCL ), Centre Hospitalier Régional Universitaire [Lille] ( CHRU Lille ), Biologie des Organismes et Ecosystèmes Aquatiques ( BOREA ), Université des Antilles ( UA ) -Centre National de la Recherche Scientifique ( CNRS ) -Université Pierre et Marie Curie - Paris 6 ( UPMC ) -Institut de Recherche pour le Développement ( IRD ) -Muséum National d'Histoire Naturelle ( MNHN ) -Université de Caen Normandie ( UNICAEN ), Normandie Université ( NU ) -Normandie Université ( NU ), Etablissement français du sang [Bourgogne-Franche-Comté] (EFS [Bourgogne-Franche-Comté]), Laboratoire Paul Painlevé - UMR 8524 (LPP), Université Jean Monnet [Saint-Étienne] (UJM), Centre National de la Recherche Scientifique (CNRS)-Université de Lille, École nationale supérieure d'architecture de Nantes (ENSA Nantes)-Ministère de la Culture et de la Communication (MCC)-École nationale supérieure d'architecture de Grenoble (ENSAG)-Centre National de la Recherche Scientifique (CNRS)-École Centrale de Nantes (ECN), Centre National de la Recherche Scientifique (CNRS)-Université des Antilles (UA)-Muséum national d'Histoire naturelle (MNHN)-Institut de Recherche pour le Développement (IRD)-Sorbonne Université (SU)-Université de Caen Normandie (UNICAEN), and Normandie Université (NU)-Normandie Université (NU) more...
- Subjects
0301 basic medicine ,medicine.medical_specialty ,[SDV]Life Sciences [q-bio] ,Human leukocyte antigen ,03 medical and health sciences ,0302 clinical medicine ,Receptors, KIR ,HLA Antigens ,Transplantation Immunology ,Humans ,Medicine ,[ SDV.IMM ] Life Sciences [q-bio]/Immunology ,Progenitor cell ,ComputingMilieux_MISCELLANEOUS ,Retrospective Studies ,Gynecology ,Transplantation ,[ SDV ] Life Sciences [q-bio] ,business.industry ,Umbilical Cord Blood Transplantation ,French ,Retrospective cohort study ,Hematology ,medicine.disease ,humanities ,language.human_language ,3. Good health ,Treatment Outcome ,030104 developmental biology ,Graft-versus-host disease ,Immunology ,language ,[SDV.IMM]Life Sciences [q-bio]/Immunology ,Cord Blood Stem Cell Transplantation ,France ,Stem cell ,business ,030215 immunology - Abstract
Impact of KIR/HLA genetic combinations on double umbilical cord blood transplantation outcomes. Results of a French multicentric retrospective study on behalf of the Societe Francophone de Greffe de Moelle et de Therapie Cellulaire (SFGM-TC) and the Societe Francophone d’Histocompatibilite et d’Immunogenetique (SFHI) more...
- Published
- 2016
- Full Text
- View/download PDF
38. Matching of MHC Class I Chain-Related Genes a and B Is Associated with Reduced Incidence of Severe Acute Graft-Versus-Host Disease after Unrelated Hematopoietic Stem Cell Transplantation
- Author
-
Myriam Labopin, Nicole Raus, Régis Peffault de Latour, Mohamad Mohty, Katharina Fleischhauer, Gérard Socié, Daniel Hanau, Nicolas Jung, Ibrahim Yakoub-Agha, Xavier Lafarge, Miriam Hoffmann, Raphael Carapito, Jordi Sierra, Philippe Moreau, Anne Cesbron, Masao Ota, Seiamak Bahram, Arnon Nagler, A. Parissiadis, Mauricette Michallet, Ryad Tamouza, Franz Claas, Gaëlle Giacometti, Myriam Labalette, Ronnie van der Holt, Pascale Loiseau, Fabio Ciceri, Didier Blaise, Eric Spierings, Meiggie Untrau, Valérie Dubois, Catherine Paillard, Luca Vago, Noel Milpied, Antoine Toubert, Hidetoshi Inoko, Sergio Querol, Christophe Picard, Angélique Pichot, Dominique Charron, Sandra Michel, Katia Gagne, Bruno Lioure, Machteld Oudshoorn, Carapito, R, Jung, N, Untrau, M, Michel, S, Pichot, A, Giacometti, G, Cesbron, A, Gagne, K, Oudshoorn, M, Van der Holt, R, Labalette, M, Spierings, E, Picard, C, Loiseau, P, Tamouza, R, Toubert, A, Hanau, D, Parissiadis, A, Dubois, V, Raus, N, Lafarge, X, Vago, L, Ciceri, F, Paillard, C, Querol, S, Sierra, J, Fleischhauer, K, Nagler, A, Hoffmann, M, Milpied, N, Michallet, M, Lioure, B, de Latour, Rp, Labopin, M, Inoko, H, Claas, F, Blaise, D, Yakoub-Agha, I, Moreau, P, Charron, D, Ota, M, Mohty, M, Socie, G, Bahram, S, Immuno-Rhumatologie Moléculaire, Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Strasbourg (UNISTRA), and Université de Strasbourg (UNISTRA)-Institut National de la Santé et de la Recherche Médicale (INSERM) more...
- Subjects
medicine.medical_treatment ,Immunology ,Medizin ,Hematopoietic stem cell transplantation ,Human leukocyte antigen ,Biochemistry ,03 medical and health sciences ,0302 clinical medicine ,medicine ,Minor histocompatibility antigen ,Cumulative incidence ,030304 developmental biology ,0303 health sciences ,Univariate analysis ,business.industry ,Donor selection ,Cell Biology ,Hematology ,3. Good health ,Transplantation ,surgical procedures, operative ,[SDV.IMM]Life Sciences [q-bio]/Immunology ,business ,CD8 ,030215 immunology - Abstract
Background: Graft-versus-host disease (GVHD) is a major cause of mortality after unrelated hematopoietic stem cell transplantations (HSCT). Despite the development of modern immunosuppressive strategies, a nearly perfectly controlled compatibility of the classical HLA genes (HLA-A, -B, -C, -DRB1, -DQB1, and -DPB1) and availability of numerous so-called minor histocompatibility antigens (e.g. HY or HA-1), its incidence remains largely unexplained to date. MIC genes (MHC class I chain-related) - a distinct lineage of MHC class I genes – are promising candidates to explain, at least partially, the incidence of GVHD in HLA-matched transplantations. MICA and MICB are highly polymorphic (100 alleles for MICA and 40 for MICB) and encode functional cell-surface glycoproteins up-regulated by cell stress. They interact with NKG2D, an activating receptor expressed on the surface of cytotoxic αβ CD8+ and γδ T lymphocytes and natural killer cells. MIC genes are already known to have a HLA-independent effect on solid graft outcomes and may play a similar role in HSCT by triggering GVHD. Objective: The objective of the present study was to determine the impact of donor/patient matching at the MICA and MICB loci on the incidence of GVHD in patients undergoing unrelated HSCT. Methods: We retrospectively analyzed a multicenter cohort of 1072 unrelated transplantations performed between 1996 and 2013. All donor-recipient pairs were fully typed at high resolution for HLA-A, -B, -C, -DRB1, -DQB1, and -DPB1 and were matched for ten of ten HLA alleles (HLA 10/10 matched). High resolution genotyping of MICA and MICB was performed by sequenced-based typing in order to define matching grades between donors and patients. The endpoints of the study were acute and chronic GVHD. Apart from HLA-DPB1 matching, statistical models were adjusted for major clinical variables which have been shown to be associated with outcome (patient’s age, patient’s and donor’s sex, patient’s and donor’s serological status for cytomegalovirus, year of transplantation, time to transplantation, transplantation center, source of stem cells, conditioning regimen, GVHD prophylaxis, treatment with anti-thymocyte globulin, disease category and severity at transplantation). Results: Of the 1072 transplantations, 134 (12.5 %) and 380 (35.4 %) were mismatched at the MICA and MICB locus, respectively. Both MICA and MICB mismatches were significantly associated with an increased incidence of severe acute GVHD (grades III-IV) in univariate and multivariate models (multivariate model: HR = 2.32, 95 % CI = 1.84-2.92; p=0.0003 for MICA and HR = 1.49, 95 % CI = 1.24-1.79; p=0.03 for MICB). At day 100 post-HSCT severe acute GVHD incidences in mismatched vs. matched transplantations were 19.62 % vs. 15.08 % and 20.00 % vs. 14.84 % for MICA and MICB, respectively (Figure 1). Chronic GVHD was associated with MICA and MICB mismatches in univariate analysis (HR = 1.55, 95 % CI = 1.27-1.89; p=0.029 for MICA and HR=1.38, 95 % CI = 1.19-1.62; p=0.03 for MICB), but showed only a trend for association in multivariate models. Figure 1 Estimated cumulative incidence curves of grades III–IV acute GVHD according to MICA (panel A) and MICB (panel B) matching status. The solid and dashed lines represent MIC matched and mismatched grafts, respectively. The Fine and Gray model was used with relapse and death considered as competing risks. Figure 1. Estimated cumulative incidence curves of grades III–IV acute GVHD according to MICA (panel A) and MICB (panel B) matching status. The solid and dashed lines represent MIC matched and mismatched grafts, respectively. The Fine and Gray model was used with relapse and death considered as competing risks. Conclusion: To date this is the largest reported MICA and MICB sequence analysis whether in HSCT or solid organ transplantation. Inclusion of MICA and MICB typing in the donor selection process may be a practical clinical strategy for lowering the risks of severe acute GVHD after unrelated HSCT. Disclosures No relevant conflicts of interest to declare. more...
- Published
- 2014
- Full Text
- View/download PDF
39. Pre-existing donor-specific antibodies are detrimental to kidney allograft only when persistent after transplantation
- Author
-
Christian Gachet, Bruno Moulin, Francoise Heibel, C. Muller, Gabriela Gautier-Vargas, Veronique Renner, A. Parissiadis, Francois Lefebre, Sophie Caillard, Jérôme Olagne, Laura Braun, Camille Becmeur, Peggy Perrin, and Noëlle Cognard more...
- Subjects
Adult ,Graft Rejection ,Male ,medicine.medical_specialty ,030232 urology & nephrology ,Urology ,030230 surgery ,Kidney ,Sensitivity and Specificity ,03 medical and health sciences ,0302 clinical medicine ,Antigen ,HLA Antigens ,Isoantibodies ,Risk Factors ,medicine ,Humans ,Renal Insufficiency ,Kidney transplantation ,Retrospective Studies ,Immunosuppression Therapy ,Transplantation ,biology ,business.industry ,Donor specific antibodies ,Histocompatibility Testing ,Graft Survival ,Middle Aged ,medicine.disease ,Allografts ,Kidney Transplantation ,Tissue Donors ,Surgery ,body regions ,surgical procedures, operative ,medicine.anatomical_structure ,Allograft rejection ,Area Under Curve ,Multivariate Analysis ,biology.protein ,Graft survival ,Female ,Antibody ,business ,Immunosuppressive Agents ,Glomerular Filtration Rate - Abstract
Donor-specific antibodies (DSA) increase the risk of allograft rejection and graft failure. They may be present before transplant or develop de novo after transplantation. Here, we studied the evolution of preformed DSA and their impact on graft outcome in kidney transplant recipients. Using the Luminex Single Antigen assay, we analyzed the sera on the day of transplantation of 239 patients who received a kidney transplant. Thirty-seven patients (15.5%) had pre-existing DSA detected the day of transplantation. After 5 years, the pre-existing DSA disappeared in 22 patients whereas they persisted in 12. Variables associated with DSA persistence were age50 years (P = 0.009), a history of previous transplantation (P = 0.039), the presence of class II DSA (P = 0.009), an MFI of preformed DSA3500 (P 0.001), and the presence of two or more DSA (P 0.001). DSA persistence was associated with a higher risk of graft loss and antibody-mediated rejection. Previously undetected preformed DSA are deleterious to graft survival only when they persist after transplantation. more...
- Published
- 2016
40. EPITOPE LOAD IS PREDECTIVE OF DE NOVO CLASS II DSA OCCURRENCE IN RENAL TRANSPLANT RECIPIENTS AFTER CONVERSION FROM CYCLOSPORINE TO EVEROLIMUS
- Author
-
Snanoudj, R., Suberbielle, C., Kamar, N., Cassuto, E., Ohlmann, S., Parissiadis, A., Merville, P., Taupin, J. L., Thierry, A., Jollet, I., Grimbert, P., Anglicheau, D., Hazzan, M., Choukroun, Gabriel, de Ligny, B. Hurault, Janbon, B., Vuiblet, V., Sayegh, J., Le Meur, Y., Morelon, E., Buechler, M., Legendre, C. H., Hertig, A., Rondeau, E., DESSAIVRE, Louise, Service de néphrologie adultes [CHU Necker], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-CHU Necker - Enfants Malades [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Département de Néphrologie et Transplantation d'organes [CHU Toulouse], Pôle Urologie - Néphrologie - Dialyse - Transplantations - Brûlés - Chirurgie plastique - Explorations fonctionnelles et physiologiques [CHU Toulouse], Centre Hospitalier Universitaire de Toulouse (CHU Toulouse)-Centre Hospitalier Universitaire de Toulouse (CHU Toulouse), Université Toulouse III - Paul Sabatier (UT3), Université de Toulouse (UT), Unité de recherche Génétique Microbienne (UGM), Institut National de la Recherche Agronomique (INRA), Etablissement Français du Sang - Grand Est (EFS - alsace strasbourg), Service de Néphrologie-transplantation-dialyse [Bordeaux], CHU Bordeaux [Bordeaux], Ischémie Reperfusion en Transplantation d’Organes Mécanismes et Innovations Thérapeutiques ( IRTOMIT), Université de Poitiers-Institut National de la Santé et de la Recherche Médicale (INSERM), Université de Poitiers, Université Paris Descartes - Paris 5 (UPD5), Labex_Transplantex (Labex_Transplantex), Institut Necker Enfants-Malades (INEM - UM 111 (UMR 8253 / U1151)), Université Paris Descartes - Paris 5 (UPD5)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Service Néphrologie et transplantation rénale Adultes [CHU Necker], CHU Necker - Enfants Malades [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille), CHU Amiens-Picardie, Mécanismes physiopathologiques et conséquences des calcifications vasculaires - UR UPJV 7517 (MP3CV), Université de Picardie Jules Verne (UPJV)-CHU Amiens-Picardie, Centre Hospitalier Universitaire [Grenoble] (CHU), Matrice extracellulaire et dynamique cellulaire - UMR 7369 (MEDyC), Université de Reims Champagne-Ardenne (URCA)-SFR CAP Santé (Champagne-Ardenne Picardie Santé), Université de Reims Champagne-Ardenne (URCA)-Université de Reims Champagne-Ardenne (URCA)-Centre National de la Recherche Scientifique (CNRS), CHRU Brest - Service de Nephrologie (CHU - BREST - Nephrologie), Centre Hospitalier Régional Universitaire de Brest (CHRU Brest), Service de Transplantation, Néphrologie et Immunologie Clinique [Hôpital Edouard Herriot, HCL], Hospices Civils de Lyon (HCL)-Hôpital Edouard Herriot [CHU - HCL], Hospices Civils de Lyon (HCL), Des Maladies Rénales Rares aux Maladies Fréquentes, Remodelage et Réparation, Université Pierre et Marie Curie - Paris 6 (UPMC)-Institut National de la Santé et de la Recherche Médicale (INSERM), CHU Tenon [AP-HP], and Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU) more...
- Subjects
[SDV] Life Sciences [q-bio] ,[SDV]Life Sciences [q-bio] ,ComputingMilieux_MISCELLANEOUS - Abstract
International audience
- Published
- 2016
41. Survenue d’une thrombopénie sévère et durable, au décours d’une greffe de moelle allogénique, imputable à l’existence chez l’hôte d’une allo-immunisation anti-HPA-1
- Author
-
A. Parissiadis, Daniel Hanau, Ana Berceanu, J.-P. Cazenave, N. Froelich, Karin Bilger, Sylvie Tourne, B. Lioure, M. Schwebel, and A. Laplace
- Subjects
business.industry ,medicine.medical_treatment ,Biochemistry (medical) ,Clinical Biochemistry ,Immunosuppression ,Hematology ,Human leukocyte antigen ,Haematopoiesis ,medicine.anatomical_structure ,ABO blood group system ,Immunology ,medicine ,Plasmapheresis ,Platelet ,Bone marrow ,business ,Autotransfusion - Abstract
A 56 year-old, multiparous woman suffering from a myeloproliferative syndrome, who had received multiple red blood cell and platelet transfusions, was the recipient of an allograft of peripheral blood stem cells derived from her HLA-A, B, DR, DQ and DP and ABO identical sister, following myeloablative conditioning. The persistence of severe, isolated thrombopenia resistant to platelet transfusions led to the discovery of anti-HLA class I allo-immunisation. As HLA compatible platelet transfusions did not result in satisfactory platelet increments, we then discovered the simultaneous presence of anti-HPA-1a allo-immunisation. Genotyping of the HPA-1 systems of the patient (HPA-1B/B) and her sister (HPA-1A/B) enabled us to elucidate the mechanism underlying the persistent thrombopenia and the inefficacy of transfusion. In fact, only transfusion of HPA-1B/B platelets (HLA compatible or incompatible) proved to be efficacious. To reduce the level of anti-HPA-1a antibodies, we performed plasmapheresis sessions and used an anti-CD20 monoclonal antibody. It was only on achieving total haematopoietic chimerism, through rapid interruption of the immunosuppression, that we obtained spontaneous normalisation of the platelet count. The present case emphasises the necessity, before undertaking any allograft of haematopoietic stem cells - even if the latter come from a strictly HLA identical member of the family - of performing a search for eventual anti-HPA allo-immunisation. more...
- Published
- 2010
- Full Text
- View/download PDF
42. Identification de nouveaux allèles HLA en séquençage nouvelle génération HOLOTYPE OMIXON : retour d’expérience de 8 laboratoires EFS
- Author
-
Blouin, Laura, primary, Bardy, Beatrice, additional, Bertrand, Gerald, additional, Bouille, Caroline, additional, Cesbron, Anne, additional, Dubois, Valérie, additional, Frassati, Coralie, additional, Jollet, Isabelle, additional, Masson, Dominique, additional, Moskovtchenko, Philippe, additional, Parissiadis, Anne, additional, Picard, Christophe, additional, Proust, Barbara, additional, Renac, Virginie, additional, Tourne, Sylvie, additional, Walencik, Alexandre, additional, Desbois, Isabelle, additional, Bliem, Cathy, additional, and Lafarge, Xavier, additional more...
- Published
- 2017
- Full Text
- View/download PDF
43. Simultaneous Development of Lymphoma in Recipients of Renal Transplants from a Single Donor: Donor Origin Confirmed by Human Leukocyte Antigen Staining and Microsatellite Analysis
- Author
-
Luc Marcellin, Thierry Hannedouche, Erwan Pencreach, Laura Braun, A. Parissiadis, Philippe Wolf, Marie-Lorraine Woehl Jaegle, Sophie Caillard, Marie-Pierre Gaub, and Bruno Moulin
- Subjects
Adult ,Male ,Lymphoma ,medicine.medical_treatment ,Lymphoproliferative disorders ,Human leukocyte antigen ,HLA Antigens ,hemic and lymphatic diseases ,medicine ,Humans ,Gene Rearrangement ,Transplantation ,Genes, Immunoglobulin ,biology ,Immunosuppression ,Gene rearrangement ,Middle Aged ,medicine.disease ,Immunohistochemistry ,Kidney Transplantation ,HLA Mismatch ,Tissue Donors ,surgical procedures, operative ,Immunology ,biology.protein ,Female ,Antibody ,Microsatellite Repeats - Abstract
Background Posttransplant lymphoproliferative disorders (PTLD) occur in 0.5% to 2.5% of cases in renal-transplant recipients. Epstein-Barr virus (EBV) is usually detected in the tumor cells, suggesting a role for this virus as an agent of B-cell proliferation. It is unusual for patients receiving allografts from the same donor to develop PTLD simultaneously. Methods we describe two patients who received renal allografts from the same donor and developed PTLD simultaneously. The presence of EBV in both tumors was confirmed. In this report, the origin of tumor cells was determined by immunohistochemical human leukocyte antigen (HLA) typing and microsatellite analysis. Clonality was studied by immunoglobulin gene rearrangement analysis. Results Our results suggest that the tumor originated from donor cells in both patients but, because immunoglobulin gene rearrangements were different, this could mean that lymphoid cells proliferate independently in each recipient. Conclusions We propose the following pathogenesis: immortalization of passenger B lymphocytes by EBV, proliferation of these cells, and development of PTLD by means of immunosuppression, antigenic stimulation, and HLA mismatch. more...
- Published
- 2005
- Full Text
- View/download PDF
44. Matching for the non-conventional MHC-I MICA gene significantly reduces the incidence of acute and chronic GVHD
- Author
-
Carapito, Raphael, Jung, Nicolas, Kwemou, Marius, Untrau, Meiggie, Michel, Sandra, Pichot, Angélique, Giacometti, Gaëlle, Macquin, Cécile, Ilias, Wassila, Morlon, Aurore, Kotova, Irina, Apostolova, Petya, Schmitt-Graeff, Annette, Cesbron, Anne, Gagne, Katia, Oudshoorn, Machteld, van der Holt, Bronno, Labalette, Myriam, Spierings, Eric, Picard, Christophe, Loiseau, Pascale, Tamouza, Ryad, Toubert, Antoine, Parissiadis, Anne, Dubois, Valérie, Lafarge, Xavier, Maumy-Bertrand, Myriam, Bertrand, Frédéric, Vago, Luca, Ciceri, Fabio, Paillard, Catherine, Querol, Sergi, Sierra, Jorge, Fleischhauer, Katharina, Nagler, Arnon, Labopin, Myriam, Inoko, Hidetoshi, von dem Borne, Peter A, Kuball, Jürgen H E, Ota, Masao, Katsuyama, Yoshihiko, Michallet, Mauricette, Lioure, Bruno, Peffault de Latour, Régis, Blaise, Didier, Cornelissen, Jan J, Yakoub-Agha, Ibrahim, Claas, Frans, Moreau, Philippe, Milpied, Noël, Charron, Dominique, Mohty, Mohamad, Zeiser, Robert, Socié, Gérard, Bahram, Seiamak, Carapito, Raphael, Jung, Nicolas, Kwemou, Marius, Untrau, Meiggie, Michel, Sandra, Pichot, Angélique, Giacometti, Gaëlle, Macquin, Cécile, Ilias, Wassila, Morlon, Aurore, Kotova, Irina, Apostolova, Petya, Schmitt-Graeff, Annette, Cesbron, Anne, Gagne, Katia, Oudshoorn, Machteld, van der Holt, Bronno, Labalette, Myriam, Spierings, Eric, Picard, Christophe, Loiseau, Pascale, Tamouza, Ryad, Toubert, Antoine, Parissiadis, Anne, Dubois, Valérie, Lafarge, Xavier, Maumy-Bertrand, Myriam, Bertrand, Frédéric, Vago, Luca, Ciceri, Fabio, Paillard, Catherine, Querol, Sergi, Sierra, Jorge, Fleischhauer, Katharina, Nagler, Arnon, Labopin, Myriam, Inoko, Hidetoshi, von dem Borne, Peter A, Kuball, Jürgen H E, Ota, Masao, Katsuyama, Yoshihiko, Michallet, Mauricette, Lioure, Bruno, Peffault de Latour, Régis, Blaise, Didier, Cornelissen, Jan J, Yakoub-Agha, Ibrahim, Claas, Frans, Moreau, Philippe, Milpied, Noël, Charron, Dominique, Mohty, Mohamad, Zeiser, Robert, Socié, Gérard, and Bahram, Seiamak more...
- Published
- 2016
45. Matching for the nonconventional MHC-I MICA gene significantly reduces the incidence of acute and chronic GVHD
- Author
-
Carapito, R. (Raphael), Jung, N. (Nicolas), Kwemou, M. (Marius), Untrau, M. (Meiggie), Michel, S. (Sandra), Pichot, A. (Angélique), Giacometti, G. (Gaëlle), Macquin, C. (Cécile), Ilias, W. (Wassila), Morlon, A. (Aurore), Kotova, I. (Irina), Apostolova, P. (Petya), Schmitt-Graeff, A. (Annette), Cesbron, A. (Anne), Gagne, K. (Katia), Oudshoorn, M. (Machteld), Holt, B. (Bronno) van der, Labalette, M. (Myriam), Spierings, E. (E.), Picard, C. (Christophe), Loiseau, P. (Pascale), Tamouza, R. (Ryad), Toubert, A. (Antoine), Parissiadis, A. (Anne), Dubois, V. (Valerie), Lafarge, X. (Xavier), Maumy-Bertrand, M. (Myriam), Bertrand, F. (Frédéric), Vago, L. (Luca), Ciceri, F. (Fabio), Paillard, C. (Catherine), Querol, S. (Sergi), Sierra, J. (Jorge), Fleischhauer, K. (Katharina), Nagler, A. (Arnon), Labopin, M. (Myriam), Inoko, H. (Hidetoshi), Borne, P.A.K. (Peter) von dem, Kuball, J. (Jürgen), Ota, M. (Masao), Katsuyama, Y. (Yoshihiko), Michallet, M. (Mauricette), Lioure, B., De Latour, R.P. (Régis Peffault), Blaise, D. (Didier), Cornelissen, J.J. (Jan), Yakoub-Agha, I. (Ibrahim), Claas, F.H.J. (Frans), Moreau, P., Milpied, N., Charron, D. (Dominique), Mohty, M. (Mohamad), Zeiser, R. (Robert), Socie, G. (Gerard), Bahram, S. (Seiamak), Carapito, R. (Raphael), Jung, N. (Nicolas), Kwemou, M. (Marius), Untrau, M. (Meiggie), Michel, S. (Sandra), Pichot, A. (Angélique), Giacometti, G. (Gaëlle), Macquin, C. (Cécile), Ilias, W. (Wassila), Morlon, A. (Aurore), Kotova, I. (Irina), Apostolova, P. (Petya), Schmitt-Graeff, A. (Annette), Cesbron, A. (Anne), Gagne, K. (Katia), Oudshoorn, M. (Machteld), Holt, B. (Bronno) van der, Labalette, M. (Myriam), Spierings, E. (E.), Picard, C. (Christophe), Loiseau, P. (Pascale), Tamouza, R. (Ryad), Toubert, A. (Antoine), Parissiadis, A. (Anne), Dubois, V. (Valerie), Lafarge, X. (Xavier), Maumy-Bertrand, M. (Myriam), Bertrand, F. (Frédéric), Vago, L. (Luca), Ciceri, F. (Fabio), Paillard, C. (Catherine), Querol, S. (Sergi), Sierra, J. (Jorge), Fleischhauer, K. (Katharina), Nagler, A. (Arnon), Labopin, M. (Myriam), Inoko, H. (Hidetoshi), Borne, P.A.K. (Peter) von dem, Kuball, J. (Jürgen), Ota, M. (Masao), Katsuyama, Y. (Yoshihiko), Michallet, M. (Mauricette), Lioure, B., De Latour, R.P. (Régis Peffault), Blaise, D. (Didier), Cornelissen, J.J. (Jan), Yakoub-Agha, I. (Ibrahim), Claas, F.H.J. (Frans), Moreau, P., Milpied, N., Charron, D. (Dominique), Mohty, M. (Mohamad), Zeiser, R. (Robert), Socie, G. (Gerard), and Bahram, S. (Seiamak) more...
- Abstract
Graft-versus-host disease (GVHD) is among the most challenging complications in unrelated donor hematopoietic cell transplantation (HCT). The highly polymorphic MHC class I chain-related gene A, MICA, encodes a stress-induced glycoprotein expressed primarily on epithelia. MICA interacts with the invariant activating receptor NKG2D, expressed by cytotoxic lymphocytes, and is located in the MHC, next to HLA-B. Hence, MICA has the requisite attributes of a bona fide transplantation antigen. Using high-resolution sequence-based genotyping of MICA, we retrospectively analyzed the clinical effect of MICA mismatches in a multicenter cohort of 922 unrelated donor HLA-A, HLA-B, HLA-C, HLA-DRB1, and HLA-DQB1 10/10 allele-matched HCT pairs. Among the 922 pairs, 113 (12.3%) were mismatched in MICA. MICA mismatches were significantly associated with an increased incidence of grade III-IV acute GVHD (hazard ratio [HR], 1.83; 95% confidence interval [CI], 1.50-2.23; P < .001), chronic GVHD (HR, 1.50; 95% CI more...
- Published
- 2016
- Full Text
- View/download PDF
46. Matching for the non-conventional MHC-I MICA gene significantly reduces the incidence of acute and chronic GVHD
- Author
-
CDL Celdiagnostiek, Infection & Immunity, MS Hematologie, Regenerative Medicine and Stem Cells, Cancer, Carapito, Raphael, Jung, Nicolas, Kwemou, Marius, Untrau, Meiggie, Michel, Sandra, Pichot, Angélique, Giacometti, Gaëlle, Macquin, Cécile, Ilias, Wassila, Morlon, Aurore, Kotova, Irina, Apostolova, Petya, Schmitt-Graeff, Annette, Cesbron, Anne, Gagne, Katia, Oudshoorn, Machteld, van der Holt, Bronno, Labalette, Myriam, Spierings, Eric, Picard, Christophe, Loiseau, Pascale, Tamouza, Ryad, Toubert, Antoine, Parissiadis, Anne, Dubois, Valérie, Lafarge, Xavier, Maumy-Bertrand, Myriam, Bertrand, Frédéric, Vago, Luca, Ciceri, Fabio, Paillard, Catherine, Querol, Sergi, Sierra, Jorge, Fleischhauer, Katharina, Nagler, Arnon, Labopin, Myriam, Inoko, Hidetoshi, von dem Borne, Peter A, Kuball, Jürgen H E, Ota, Masao, Katsuyama, Yoshihiko, Michallet, Mauricette, Lioure, Bruno, Peffault de Latour, Régis, Blaise, Didier, Cornelissen, Jan J, Yakoub-Agha, Ibrahim, Claas, Frans, Moreau, Philippe, Milpied, Noël, Charron, Dominique, Mohty, Mohamad, Zeiser, Robert, Socié, Gérard, Bahram, Seiamak, CDL Celdiagnostiek, Infection & Immunity, MS Hematologie, Regenerative Medicine and Stem Cells, Cancer, Carapito, Raphael, Jung, Nicolas, Kwemou, Marius, Untrau, Meiggie, Michel, Sandra, Pichot, Angélique, Giacometti, Gaëlle, Macquin, Cécile, Ilias, Wassila, Morlon, Aurore, Kotova, Irina, Apostolova, Petya, Schmitt-Graeff, Annette, Cesbron, Anne, Gagne, Katia, Oudshoorn, Machteld, van der Holt, Bronno, Labalette, Myriam, Spierings, Eric, Picard, Christophe, Loiseau, Pascale, Tamouza, Ryad, Toubert, Antoine, Parissiadis, Anne, Dubois, Valérie, Lafarge, Xavier, Maumy-Bertrand, Myriam, Bertrand, Frédéric, Vago, Luca, Ciceri, Fabio, Paillard, Catherine, Querol, Sergi, Sierra, Jorge, Fleischhauer, Katharina, Nagler, Arnon, Labopin, Myriam, Inoko, Hidetoshi, von dem Borne, Peter A, Kuball, Jürgen H E, Ota, Masao, Katsuyama, Yoshihiko, Michallet, Mauricette, Lioure, Bruno, Peffault de Latour, Régis, Blaise, Didier, Cornelissen, Jan J, Yakoub-Agha, Ibrahim, Claas, Frans, Moreau, Philippe, Milpied, Noël, Charron, Dominique, Mohty, Mohamad, Zeiser, Robert, Socié, Gérard, and Bahram, Seiamak more...
- Published
- 2016
47. Identification de nouveaux allèles HLA en séquençage nouvelle génération HOLOTYPE OMIXON : retour d’expérience de 8 laboratoires EFS
- Author
-
Gerald Bertrand, Alexandre Walencik, Isabelle Jollet, Philippe Moskovtchenko, Béatrice Bardy, Cathy Bliem, Isabelle Desbois, Dominique Masson, Caroline Bouille, Valérie Dubois, Anne Cesbron, Xavier Lafarge, Coralie Frassati, Barbara Proust, Virginie Renac, A. Parissiadis, Sylvie Tourne, Christophe Picard, and Laura Blouin more...
- Subjects
03 medical and health sciences ,0302 clinical medicine ,Biochemistry (medical) ,Clinical Biochemistry ,Hematology ,030204 cardiovascular system & hematology ,030215 immunology - Abstract
Huit laboratoires pilotes de l’EFS ont deploye en 2016 une technique de sequencage HLA nouvelle generation HOLOTYPE (OMIXON). Depuis, des typages ont ete menes sur les locus A et B (13704), C, DRB1, DRB3, DQB1 (13516), DPB1 et DQA1 (4735). Deuxx cent dix-sept nouveaux polymorphismes ont ete identifies, representant en moyenne 2.3 nouveaux alleles/1000 typages/locus. Ces mutations ont ete differenciees selon qu’elles s’accompagnent d’une modification de la resolution 6 digits seulement (n = 65, sequence proteique inchangee), d’une modification de la resolution 4 digits, mais pas de la haute resolution (n = 117) ou d’une modification de la haute resolution ou de la creation d’un allele nul (n = 35, modification de l’expression des domaines presentant les peptides antigeniques). Les frequences observees pour chacun de ces types de mutations/1000 typages/locus sont : A* : 0.6, 0.1, 0.1 ; B* : 0.6, 1.1, 0.4 ; C* : 1, 2.4, 0.4 ; DRB1* : 1.2, 1.6, 0.3 et DRB3* 0.0, 0.1, 0.0 ; DQB1* : 0.6, 1, 0.1 ; DPB1* : 0.6, 1.7, 0 ; DQA1* : 1.7, 1.7, 0.6. Ces donnees confirment le faible polymorphisme des genes de la classe II en dehors de l’exon 2. Neanmoins, le plus grand nombre des mutants modifiant la sequence proteique concernent les domaines non impliques dans la presentation de l’antigene, particulierement pour les locus C, DRB1, DPB1 et DQA1 car non explores systematiquement avant le NGS. Deux nouveaux alleles nuls HLA-B* et C* (indetectables par les autres methodes de typage : codon stop dans l’exon 1) ont ete identifies qui auraient pu constituer un mismatch pour une allogreffe non apparentee. Le NGS permet donc de detecter des mutants ayant un impact clinique reel (alleles nuls) ou qui reste a estimer (alleles exprimes) more...
- Published
- 2017
- Full Text
- View/download PDF
48. Pre-existing donor-specific antibodies are detrimental to kidney allograft only when persistent after transplantation
- Author
-
Caillard, Sophie, primary, Becmeur, Camille, additional, Gautier-Vargas, Gabriela, additional, Olagne, Jerome, additional, Muller, Clotilde, additional, Cognard, Noelle, additional, Perrin, Peggy, additional, Braun, Laura, additional, Heibel, Francoise, additional, Lefebre, Francois, additional, Renner, Veronique, additional, Gachet, Christian, additional, Moulin, Bruno, additional, and Parissiadis, Anne, additional more...
- Published
- 2016
- Full Text
- View/download PDF
49. An intronic mutation responsible for a low level of expression of an HLA-A*24 allele
- Author
-
M. M. Tongio, M. Laforet, Huguette Bausinger, N Froelich, A. Parissiadis, and B Pfeiffer
- Subjects
Genetics ,Immunology ,General Medicine ,Human leukocyte antigen ,C957T ,Biology ,Biochemistry ,Molecular biology ,Stop codon ,HLA-A ,Frameshift mutation ,Exon ,Intronic Mutation ,Immunology and Allergy ,Allele - Abstract
HLA class I typing performed in parallel by molecular biology and serology has revealed cases where an HLA class I allele was identified but the corresponding antigen on the cell surface was not detected. In the present report, we describe three members of a family in whom an HLA-A24 allele identified at the molecular level was typed as A "blank" by lymphocytotoxicity. This serologically blank antigen was nevertheless faintly detectable by isoelectric focusing (IEF) and FACS analyses. Sequencing of the HLA-A*24 allele from the promoter region to the eighth exonic region revealed a point mutation in the acceptor site of the second intron as compared to the normal HLA-A*24 allele. This mutation could lead to incorrect processing of mRNA through a cryptic acceptor site located at the beginning of the third exon and hence to alternative splicing with a frame shift introducing an early stop codon into the fourth exon. more...
- Published
- 1997
- Full Text
- View/download PDF
50. A nucleotide insertion in exon 4 is responsible for the absence of expression of an HLA-A*01 allele
- Author
-
N Froelich, M. Laforet, A. Schell, A. Parissiadis, M. M. Tongio, M.-L. Woehl-Jaegle, B. Faller, J.-P. Cazenave, and B Pfeiffer
- Subjects
Genetics ,Immunology ,General Medicine ,Human leukocyte antigen ,C957T ,Biology ,Biochemistry ,Molecular biology ,Stop codon ,Frameshift mutation ,HLA-A ,Exon ,Antigen ,Immunology and Allergy ,Allele - Abstract
HLA class I typing performed in parallel by molecular biology and serology has revealed cases where an HLA class I allele was identified whereas the corresponding antigen was not detected on the cell surface. In the present report, we describe four members of a family in whom an HLA-A1 allele identified at the molecular level was typed as A "blank" by lymphocytotoxicity. This serologically blank antigen was undetectable by isoelectric focusing (IEF). Sequencing of the HLA-A*01 allele from the promoter region to the eighth exonic region revealed insertion of a "C" nucleotide at the beginning of the fourth exon as compared to the common HLA-A*0101 allele. This mutation causes a frame shift, giving rise to an early stop codon in the fourth exon. more...
- Published
- 1997
- Full Text
- View/download PDF
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.